PFIZER INC

PFE

Held by 4 specialist biotech funds

High Convergence

4 funds opened new positions. Next phase3 readout (PhXA41): Feb 1994. Short interest: 2.6% of float.

Drug Manufacturers - GeneralCEO: Albert BourlaIPO: 1972Website ↗

Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.

Catalysts

Phase 3PositiveQ1 1994PhXA41Glaucoma, Open Angle Glaucoma, Ocular HypertensionNCT00751127

Primary: to demonstrate the IOP-reducing effect of PhXA41 is comparable to that of timolol at the end of 6 months of treatment. (6 mos)Enrollment:268/268Sites: 17RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q2 1998Meningococcal CMeningitis, MeningococcalNCT00314041

Primary: Antibody responses to MnCC and concomitant vaccinesEnrollment:Target 240RANDOMIZED, DOUBLE, PREVENTION

Phase 2Q1 1999chemotherapyLeukemiaNCT00003673

Enrollment:Target 55Sites: 10TREATMENT

Phase 3Q2 1999Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)Encephalitis, Tick-borneNCT00161746

Sites: 7RANDOMIZED, DOUBLE, PREVENTION

Phase 3PositiveQ3 2000Inhaled human insulinDiabetes Mellitus, Type 1NCT00424437

Primary: Primary outcome is 24 week change in baseline in HbA1cEnrollment:Target 320Sites: 36RANDOMIZED, TREATMENT

Phase 3Q2 2001leflunomideBrain and Central Nervous System TumorsNCT00003293

Sites: 35RANDOMIZED, TREATMENT

Phase 2Q1 2002prinomastatBrain and Central Nervous System TumorsNCT00004200

Sites: 1RANDOMIZED, TREATMENT

Phase 2Q1 2002PantoprazolePeptic Ulcer HemorrhageNCT00037570

Enrollment:12/12Sites: 6RANDOMIZED, PREVENTION

Phase 3Q3 2002Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)Encephalitis, Tick-borneNCT00161876

Enrollment:Target 3,973Sites: 8NON_RANDOMIZED

Phase 3Q4 2002linezolidFebrile NeutropeniaNCT00035425

Primary: Clinical efficacy of linezolid when administered intravenously as compared to intravenously administered vancomycin in the empiric treatment of oncology patients with febrile neutropenia with suspected gram-positive infections. (7-28 days)Enrollment:120/120Sites: 40RANDOMIZED, DOUBLE, TREATMENT

Phase 2NegativeQ1 2003CelecoxibNeoplasm Metastasis, Colorectal NeoplasmsNCT00037180

Primary: Incidence of NCI CTC grade 2-4 diarrhea during the first cycle (6 weeks) of CPT-11/5-FU/LV chemotherapyEnrollment:Target 212Sites: 12RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q1 2003PN-152,243)/PN-196,444SarcomaNCT00038311

Primary: To evaluate the effectiveness of intravenous rhTPO versus placebo in reducing the cumulative proportion of patients who experience severe chemotherapy induced thrombocytopenia.Enrollment:Target 120Sites: 6RANDOMIZED, DOUBLE, PREVENTION

Phase 3Q2 2003sumaniroleParkinson DiseaseNCT00036218

Primary: Change from baseline in UPDRS (Unified Parkinson's Disease Rating Scale) II + III total scores at end of maintenance, for sumanirole compared to placeboEnrollment:Target 600Sites: 102RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q2 2003Venlafaxine ERPanic DisorderNCT00044772

Enrollment:653/653TREATMENT

Phase 3Q3 2003Laparoscopic Cholecystectomy, PainNCT00661635

Primary: Patient's Global Evaluation of Study Medication (Day 2 and Day 3)Enrollment:490/490Sites: 65RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q1 2004clarithromycin extended release (ER)PneumoniaNCT00643227

Primary: sponsor assessment of clinical response (clinical cure rate) in the Clinical Per Protocol population (Test of Cure (TOC) visit (Day 14-21))Enrollment:504/504Sites: 72RANDOMIZED, DOUBLE, TREATMENT

Phase 2PositiveQ3 2004VareniclineSmokingNCT00635401

Primary: Carbon monoxide (CO)-confirmed 4-week continuous quit rate (4-week CQR) from Weeks 4 to 7. (Weeks 4-7)Enrollment:30/30Sites: 8NON_RANDOMIZED, TREATMENT

Phase 3PositiveQ3 2004ReFacto AFHemophilia ANCT00037544

TREATMENT

Phase 2Q3 2004Anidulafungin, VER002CandidiasisNCT00041704

Enrollment:19/19Sites: 1NON_RANDOMIZED, TREATMENT

Phase 2Q4 2004EKB-569Colorectal Neoplasms, Colonic Neoplasms, Rectal NeoplasmsNCT00072748

Enrollment:63/63NON_RANDOMIZED, TREATMENT

Phase 3Q4 2004GabapentinTransient InsomniaNCT00666770

Primary: Latency to persistent sleep as measured by polysomnography (Hour +8)Enrollment:309/309Sites: 5RANDOMIZED, TRIPLE, TREATMENT

Phase 2NegativeQ4 2004EAA-090Diabetes Mellitus, Diabetic Neuropathy, PainfulNCT00073034

RANDOMIZED, DOUBLE, TREATMENT

Phase 3NegativeQ1 2005SynercidGram-Positive Bacterial InfectionsNCT00240747

Primary: Population pharmacokineticsSites: 6NON_RANDOMIZED, TREATMENT

Phase 3Q1 2005GabapentinTransient InsomniaNCT00667108

Primary: Subjective sleep latency (Hour +8)Enrollment:784/784Sites: 8RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q1 2005GenotropinGrowth DisordersNCT00174408

Primary: Height, height velocityEnrollment:Target 110RANDOMIZED, TREATMENT

Phase 2Q1 2005ZiprasidoneSchizophrenia, Bipolar Disorder, Schizoaffective DisorderNCT00650611

Primary: Adverse events at Baseline, Day 4, and Weeks 1, 2, 3, 4, 8, 12, 18, and 27. (27 weeks)Enrollment:63/63Sites: 17RANDOMIZED, TREATMENT

Phase 2Q2 2005Letrozole / Temsirolimus (CCI-779)Breast NeoplasmsNCT00062751

Primary: Percentage of Participants With Objective Response (OR) (Baseline, every 4 cycles (1 cycle is defined as a 14 day duration) up to Cycle 25, then every 6 cycles until disease progression)Enrollment:108/108RANDOMIZED, TREATMENT

Phase 3NegativeQ2 2005Azithromycin/ChloroquineMalaria, FalciparumNCT00084240

Primary: parasite clearanceEnrollment:32/32RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q2 2005capravirineHIV InfectionsNCT00052117

Primary: To determine the optimal safe and effective dose of capravirine in combination with Kaletra plus at least 2 NRTIsEnrollment:Target 300RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q2 2005GabapentinTransient InsomniaNCT00666575

Primary: Adverse Events (Day 45)Enrollment:Target 2,105Sites: 23RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q2 2005Parecoxib and placeboPain, PostoperativeNCT00143169

Primary: To validate the morphine-sparing effect of parecoxib administered intravenously for the treatment of Chinese subjects with postoperative pain following gynecological or orthopedic surgery.Enrollment:Target 220Sites: 8RANDOMIZED, DOUBLE, TREATMENT

Phase 3PositiveQ2 2005PregabalinFibromyalgiaNCT00645398

Primary: Endpoint mean pain score derived from the subject's daily pain diary (Endpoint)Enrollment:751/751Sites: 102RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q3 2005celecoxib and ibuprofen SRPain, PostoperativeNCT00150280

Primary: To validate the analgesic efficacy of celecoxib compared with ibuprofen SR in the management of acute pain post orthopedic or gynecological surgeryEnrollment:Target 132Sites: 6RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q3 2005PregabalinSeizure Disorder, PartialNCT00141336

Primary: Safety TolerabilityEnrollment:Target 750Sites: 103NON_RANDOMIZED, TREATMENT

Phase 3Q3 2005LinezolidBacterial Infections, Gram-Positive Bacterial Infections, BacteremiaNCT00037050

Primary: The empiric treatment of patients with complicated skin and skin structure infections (cSSSI) related to an indwelling catheter;Enrollment:739/739RANDOMIZED, TREATMENT

Phase 3PositiveQ3 2005Amlodipine/atorvastatin single pillHypertension, HyperlipidemiaNCT00143234

Primary: To evaluate the efficacy of amlodipine/atorvastatin therapy by assessing the percentage of intent-to-treat subjects achieving both BP and lipid treatment goals (JNC VII and NCEP ATP III)Enrollment:Target 1,825Sites: 118NON_RANDOMIZED, TREATMENT

Phase 2NegativeQ3 2005CP-724,714Breast Neoplasms, Neoplasm MetastasisNCT00102895

Primary: Tumor ResponseEnrollment:Target 25NON_RANDOMIZED, TREATMENT

Phase 3Q4 2005TigecyclineBacterial InfectionsNCT00205816

Primary: responseEnrollment:26/26Sites: 3NON_RANDOMIZED, TREATMENT

Phase 3Q1 2006UK-390,957EjaculationNCT00219609

Primary: Assessment of safetyEnrollment:Target 1,058Sites: 82NON_RANDOMIZED, TREATMENT

Phase 3PositiveQ2 2006varenicline (CP-526,555)Smoking CessationNCT00143325

Primary: Continuous abstinence for the last 4 weeks of varenicline and NRT (Nicotine Replacement Therapy) treatment periodEnrollment:Target 730Sites: 22RANDOMIZED, DOUBLE, TREATMENT

Phase 3PositiveQ3 2006pregabalinPartial SeizuresNCT00141258

Primary: Response ratio (RRatio or symmetrized percent change) for all partial seizuresEnrollment:178/178Sites: 5RANDOMIZED, DOUBLE, TREATMENT

Phase 3NegativeQ3 2006Cefazolin IVBacteremia, Gram-Positive Bacterial InfectionsNCT00108433

Primary: Number of Participants With Microbiological Response at Test-of-Cure (TOC) Visit (Short term follow-up (STFU) visit for TOC (2 to 3 weeks after the last dose of study medication))Enrollment:61/61Sites: 17RANDOMIZED, TREATMENT

Phase 2NegativeQ4 2006GAP-486 (ZP-123)ArrhythmiaNCT00137293

Primary: This study takes place within 24 hours. The measure to determine the effect of the intervention will be the difference in values from the baseline electrophysiology study, and the values obtained after intervention within the test drug.Enrollment:Target 30Sites: 7RANDOMIZED, DOUBLE

Phase 3Q4 2006SomatropinGrowth Hormone Deficiency, Growth RetardationNCT00174278

Primary: The main efficacy variable is the height SDS (SEMPE) before and after treatment.Enrollment:Target 14Sites: 1NON_RANDOMIZED, TREATMENT

Phase 3Q4 2006Hemophilia ANCT00141843

Primary: To determine the incidence rate of Factor VIII inhibitors in the study patient population.To establish bioequivalence of ReFacto AF as compared to Advate using the one stage Factor VIII activity assay.Enrollment:Target 100Sites: 41RANDOMIZED, DOUBLE, PREVENTION

Phase 3Q4 2006ZmaxOtitis MediaNCT00360100

Primary: Treatment-related vomiting on Day 1, which is based directly on the collected observed or voluntarily reported vomiting.Enrollment:120/120Sites: 10RANDOMIZED, DOUBLE, TREATMENT

Phase 3PositiveQ4 2006TigecyclineBacterial PneumoniaNCT00080496

Primary: The co-primary efficacy endpoints are clinical response at the TOC assessment for the clinically evaluable population and the clinical modified intent-to-treat population.Enrollment:Target 430Sites: 29RANDOMIZED, DOUBLE, TREATMENT

Phase 2NegativeQ4 2006exemestaneBreast NeoplasmsNCT00040014

Primary: To determine the pharmacodynamic equivalence at steady state of the IM formulation of exemestane with the oral formulation in terms of plasma estrone sulphate inhibitory effect in postmenopausal women with advanced breast cancer.Enrollment:Target 100Sites: 1RANDOMIZED, TREATMENT

Phase 3Q1 2007Dexmedetomidine HCL InjectionAwake Fiberoptic IntubationNCT00383890

Primary: The percentage of subjects requiring rescue midazolam to achieve and/or maintain proper sedation levels throughout the study drug infusion (At baseline and 15 minutes after starting study drug (prior to topicalization), and every 3 minutes thereafter throughout study drug infusion, at the end of topicalization, and prior to administration of any rescue medication.)Enrollment:124/124Sites: 17RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q2 2007Azithromycin SRAcute BronchitisNCT00360464

Primary: The primary endpoint is investigator's clinical efficacy at Day 8.Enrollment:64/64Sites: 19NON_RANDOMIZED, TREATMENT

Phase 2Q2 2007EdotecarinBreast Neoplasms, Neoplasm MetastasisNCT00067314

Primary: To assess the anti-tumor activity of single-agent Edotecarin by determining the objective response rateEnrollment:Target 65Sites: 19NON_RANDOMIZED, TREATMENT

Phase 3Q2 2007XalacomGlaucoma, Open-Angle, Ocular HypertensionNCT00159653

Primary: The mean IOP measurements obtained in the study eye at each time pointEnrollment:500/500Sites: 55RANDOMIZED, DOUBLE, TREATMENT

Phase 3PositiveQ2 2007Varenicline tartrateSmoking CessationNCT00371813

Primary: To compare 12 weeks of treatment with varenicline 1 mg BID to placebo for smoking cessation, and to evaluate continuous abstinence from smoking for 12 weeks after the treatment period.Enrollment:334/334Sites: 14RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q3 2007PD 0348292Venous ThrombosisNCT00306254

Primary: The primary efficacy endpoint is the incidence of total venous thromboembolism (including all proximal and distal deep vein thrombosis [DVT] and pulmonary embolism [PE])Enrollment:Target 1,225Sites: 134RANDOMIZED, DOUBLE, PREVENTION

Phase 3PositiveQ3 2007PegvisomantAcromegalyNCT00143416

Primary: To evaluate the safety and efficacy of long-term B2036-PEG therapy in patients with acromegalyEnrollment:Target 16Sites: 8NON_RANDOMIZED, TREATMENT

Phase 3NegativeQ3 2007Zoloft (Sertraline)Stress Disorders, Post-TraumaticNCT00150306

Primary: The primary efficacy parameter is the University of California at Los Angeles Post-Traumatic Stress Disorder Index for DSM-IV (UCLA PTSD-I).Enrollment:Target 160Sites: 23RANDOMIZED, DOUBLE, TREATMENT

Phase 2NegativeQ3 2007naproxenOsteoarthritisNCT00418782

Primary: To determine the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of oral multiple doses of CE 224,535 in subjects with OA of the knee (ongoing)Enrollment:212/212Sites: 46RANDOMIZED, DOUBLE, TREATMENT

Phase 2NegativeQ4 2007[S,S]-Reboxetine + PregabalinPainNCT00334685

Primary: The numerical pain intensity rating scale is used to assess pain and a change from baseline in pain score for week 10 will be calculated (Week 10)Enrollment:136/136Sites: 83RANDOMIZED, DOUBLE, TREATMENT

Phase 2NegativeQ4 2007PPM-204Diabetes MellitusNCT00425919

Primary: Fasting Plasma GlucoseEnrollment:Target 500Sites: 68RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q4 2007Levonorgestrel/Ethinyl EstradiolPremenstrual Syndrome, Menstruation DisturbancesNCT00195559

Primary: Mean change in average Daily Record of Severity of Problems (DRSP) 21-item total daily scoreEnrollment:Target 526Sites: 51RANDOMIZED, DOUBLE, PREVENTION

Phase 2NegativeQ4 2007PHA-794428Growth Hormone DeficiencyNCT00308464

Primary: Responder status at visits 9 (week 4) and 14 (week 7), where responder is defined as a patient who has achieved an IGF-1 level above the mid-point of the age-related normal range.Enrollment:Target 136Sites: 35RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q4 2007levonorgestrel/ethinyl estradiolMenstruation Disturbances, Premenstrual SyndromeNCT00128934

Primary: Mean change in average Daily Record of Severity of Problems (DRSP) 21-item total daily scoreEnrollment:Target 744Sites: 83RANDOMIZED, DOUBLE, PREVENTION

Phase 3PositiveQ4 2007pregabalinDiabetic Neuropathies, NeuralgiaNCT00141219

Primary: Daily Pain Rating Scale (DPRS)- Mean Pain Score (ITT Population) (Endpoint- Week 8 or Early Discontinuation)Enrollment:241/241Sites: 10RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2NegativeQ1 2008PF-02545920SchizophreniaNCT00570063

Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) at Day 21: Total Score (Baseline (Day 1), Day 21)Enrollment:35/35Sites: 10RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q1 2008Azithromycin plus chloroquineFalciparum MalariaNCT00282919

Primary: Percentage of Participants With Parasite Clearance at Day 28 (Day 28)Enrollment:110/110Sites: 2NON_RANDOMIZED, TREATMENT

Phase 2Q2 2008Placebo; oralDental PainNCT00663767

Primary: Assess the efficacy of the study drug dosed postoperatively in terms of total pain relief (TOTPAR). (6 hours post-dose)Enrollment:250/250Sites: 2RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q2 2008UK-369,003Urinary Bladder, OveractiveNCT00479505

Primary: This is an estimation study with no primary endpoint. There are efficacy endpoints. (12 Weeks)Enrollment:Target 275Sites: 52RANDOMIZED, TRIPLE, TREATMENT

Phase 3NegativeQ2 2008CisplatinCarcinoma, Non-Small-Cell LungNCT00254904

Primary: Overall Survival (656 Events)Enrollment:839/839Sites: 120RANDOMIZED, TREATMENT

Phase 2Q3 2008placeboArthritis, RheumatoidNCT00383188

Primary: Percentage of Participants Achieving American College of Rheumatology 20 Percent (%) (ACR 20) Response at Week 12 (Week 12)Enrollment:305/305Sites: 48RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q3 2008Smoking CessationNCT00285012

Primary: Number of Subjects With Four Week Continuous Quit Rate (CQR) (Week 9 through Week 12)Enrollment:504/504Sites: 32RANDOMIZED, TRIPLE, TREATMENT

Phase 3PositiveQ3 2008fesoterodine fumarateOveractive BladderNCT00444925

Primary: Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 12 (End of Treatment). (Baseline, Week 12)Enrollment:1,712/1,712Sites: 178RANDOMIZED, TRIPLE, TREATMENT

Phase 3NegativeQ3 2008PF-3512676 + Paclitaxel + CarboplatinCarcinoma, Non-Small-Cell LungNCT00254891

Primary: Overall Survival (656 Events)Enrollment:828/828Sites: 191RANDOMIZED, TREATMENT

Phase 2Q3 2008PF-00734200 30 mg QDDiabetes Mellitus, Type 2NCT00618007

Primary: HbA1c (12 weeks)Enrollment:289/289Sites: 79RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ3 200813vPnCVaccines, Pneumococcal Conjugate VaccineNCT00574795

Primary: Percentage of Participants Achieving Antibody Level ≥ 0.35 μg/mL in the 13vPnC Group After the 3-Dose Infant Series (one month after 3-dose infant series (at 7 months of age))Enrollment:193/193Sites: 24NON_RANDOMIZED, PREVENTION

Phase 2PositiveQ3 2008Arthritis, RheumatoidNCT00603512

Primary: Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12 (Week 12)Enrollment:140/140Sites: 18RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q4 2008ZiprasidoneSchizophreniaNCT00174447

Primary: Number of Participants With Categorical Scores on Clinical Global Impression - Improvement (CGI-I) (Baseline, 3 months, 6 months, 1 year, 3 years, 5 years, End of Study [LOCF])Enrollment:43/43Sites: 14NON_RANDOMIZED, TREATMENT

Phase 2NegativeQ4 2008PF-00885706Gastroesophageal Reflux DiseaseNCT00730665

Primary: Complete resolution of heartburn and regurgitation. [i.e. no more than one day with either mild heartburn or regurgitation over the seven days prior to the assessment time-point (Visit 6 and Visit 8)] (28 days)Enrollment:81/81Sites: 38RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q4 2008PH-797804Neuralgia, PostherpeticNCT00614705

Primary: Change from baseline to endpoint in weekly average pain score using the 11-point daily pain rating scale (4 weeks)Enrollment:80/80Sites: 25RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q4 2008VoriconazoleAspergillosisNCT00159822

Primary: Number of Subjects With Successful Global Outcome at 6 Months: Chronic Bronchopulmonary Aspergillosis (at 6 months of treatment)Enrollment:48/48Sites: 18NON_RANDOMIZED, TREATMENT

Phase 3PositiveQ4 2008ZiprasidoneBipolar Disorder, Depression, BipolarNCT00483548

Primary: Change From Baseline to Week 6 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score (Baseline, Week 6)Enrollment:298/298Sites: 70RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3NegativeQ1 2009AG-013736Carcinoma, Pancreatic DuctalNCT00471146

Primary: Overall Survival (OS) (Baseline until death or at least 1 year after the randomization of last participant)Enrollment:630/630Sites: 204RANDOMIZED, DOUBLE, TREATMENT

Phase 2PositiveQ1 2009AG013736Thyroid NeoplasmsNCT00094055

Primary: Percentage of Participants With Objective Response (OR) (Baseline until the date of first documented progression or discontinuation from the study due to any cause, assessed every 8 weeks up to 206 weeks)Enrollment:60/60Sites: 9NON_RANDOMIZED, TREATMENT

Phase 3NegativeQ1 2009CP-945,598 Treatment AObesityNCT00375401

Primary: Proportion of subjects with 5% weight loss (1 year)Enrollment:2,536/2,536Sites: 82RANDOMIZED, DOUBLE, TREATMENT

Phase 3PositiveQ1 2009FesoterodineOveractive Bladder SyndromeNCT00546637

Primary: Numerical Change From Baseline in Micturition-Related Urgency Episodes Per 24 Hours at Week 12 (Baseline, Week 12)Enrollment:947/947Sites: 137RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q1 2009PF-00610355Pulmonary Disease, Chronic ObstructiveNCT00783406

Primary: To characterize the single dose pharmacokinetics of inhaled PF-00610355 in COPD patients. (up to 8 days post dose)Enrollment:Target 20Sites: 2RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q2 2009SunitinibBreast NeoplasmsNCT00373256

Primary: Progression-Free Survival (PFS) (From date of randomization through Day 1 and every 8 weeks thereafter up to 18 months or death)Enrollment:488/488Sites: 250RANDOMIZED, TREATMENT

Phase 3Q2 2009PregabalinPain, Postoperative, Hernia, InguinalNCT00551135

Primary: Modified Brief Pain Inventory-Short Form (mBPI-sf): Worst Pain 24 Hours Post Surgery (24 hours post surgery)Enrollment:425/425Sites: 42RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q3 2009ARRY-438162, MEK inhibitor; oralRheumatoid ArthritisNCT00650767

Primary: American College of Rheumatology 20% (ACR20) Response Rate at Week 12 (Week 12)Enrollment:201/201Sites: 35RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ3 2009tanezumabArthritis, OsteoarthritisNCT00733902

Primary: Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale at Week 16: Baseline Observation Carried Forward (BOCF) (Baseline (Day 1), Week 16)Enrollment:697/697Sites: 82RANDOMIZED, DOUBLE, TREATMENT

Phase 2PositiveQ3 2009CP-690,550PsoriasisNCT00678210

Primary: Percentage of Participants Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI 75) Score at Week 12 (Week 12)Enrollment:197/197Sites: 44RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q4 2009PF-04383119 (tanezumab)Osteoarthritis, KneeNCT00669409

Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) (Day 1 up to Day 92 for tanezumab 10, 25, 50 mcg/kg group and matching placebo group (Part 1, 2); Day 1 up to Day 120 for tanezumab 100 mcg/kg group and matching placebo group (Part 1, 2), 200 mcg/kg group and matching placebo group (Part 1))Enrollment:83/83Sites: 12RANDOMIZED, TRIPLE, TREATMENT

Phase 3NegativeQ4 2009Sunitinib + CapecitabineBreast NeoplasmsNCT00435409

Primary: Progression Free Survival (PFS) (Baseline until disease progression (up to 3 years from first dose))Enrollment:442/442Sites: 169RANDOMIZED, TREATMENT

Phase 2Q1 2010TanezumabChronic Prostatitis With Chronic Pelvic Pain SyndromeNCT00826514

Primary: Change From Baseline in Average Daily Pain Score at Week 6 (Baseline, Week 6)Enrollment:62/62Sites: 44RANDOMIZED, DOUBLE, TREATMENT

Phase 3PositiveQ1 2010pregabalinDiabetic Neuropathy, PainfulNCT00553280

Primary: Summary of Adverse Events (53 weeks)Enrollment:123/123Sites: 27NON_RANDOMIZED, TREATMENT

Phase 2NegativeQ1 2010TRU-015Arthritis, RheumatoidNCT00634933

Primary: Percentage of Participants With an American College of Rheumatology 50% (ACR 50) Response at Week 24 (Week 24)Enrollment:222/222Sites: 65RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q2 2010EXC 001Scar PreventionNCT01037413

Primary: Expert Panel Scar Assessment Score at Week 12 (Part B: Week 12)Enrollment:25/25Sites: 5RANDOMIZED, DOUBLE, TREATMENT

Phase 3PositiveQ2 2010tanezumab 10 mgOsteoarthritisNCT00863304

Primary: Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale at Week 16: Baseline Observation Carried Forward (BOCF) (Baseline, Week 16)Enrollment:849/849Sites: 95RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q2 2010Smoking CessationNCT00644969

Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) (Baseline up to 30 days after last dose of study treatment or up to Week 16)Enrollment:128/128Sites: 14RANDOMIZED, DOUBLE

Phase 3Q2 2010EsreboxetineFibromyalgiaNCT00796601

Primary: Change from baseline to 3 and 6 months in the mean daily pain rating score measured by the 11 point pain intensity Numerical Rating Scale (NRS). (6 months)0RANDOMIZED, DOUBLE, TREATMENT

Phase 3PositiveQ2 2010desvenlafaxine succinate (DVS) SRVasomotor SymptomsNCT00683800

Primary: Change From Baseline in the Average Daily Number of Moderate to Severe Hot Flushes at Week 4 (Baseline and Week 4)Enrollment:2,186/2,186Sites: 121RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q2 2010CP-533, 536Tibial FracturesNCT00533377

Primary: Time to fracture healing compared with placebo (24 weeks)Enrollment:276/276Sites: 56RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q2 2010CelecoxibAnkylosing SpondylitisNCT00762463

Primary: Change From Baseline in Participant's Assessment of Global Pain Intensity at Week 6 (Baseline, Week 6)Enrollment:240/240Sites: 5RANDOMIZED, DOUBLE, TREATMENT

Phase 3NegativeQ3 2010erlotinibCarcinoma, Non-Small Cell LungNCT00457392

Primary: Overall Survival (OS) (Baseline to death or 28 days after last dose for the last participant)Enrollment:960/960Sites: 204RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q3 2010CelecoxibPainNCT01062113

Primary: Efficacy Rate (Percentage) of Patient's Impression (2 hours post-additional dose)Enrollment:255/255Sites: 22RANDOMIZED, DOUBLE, TREATMENT

Phase 2NegativeQ3 2010ICA-105665EpilepsyNCT00979004

Primary: Change in photosensitivity response (begin 1 hr post dose for 8 hours)Enrollment:13/13Sites: 3RANDOMIZED, SINGLE, TREATMENT

Phase 3Q4 2010Fragmin/ Dalteparin SodiumDiabetic Foot UlcerNCT00662831

Primary: Number of Participants With Greater Than or Equal to 50 Percent Reduction in Ulcer Surface Area Including Intact Skin Healing (Week 24 [end of treatment (EOT)] or early termination)Enrollment:276/276Sites: 63RANDOMIZED, DOUBLE, TREATMENT

Phase 2NegativeQ4 2010TanezumabDiabetic Peripheral NeuropathyNCT01087203

Primary: Change From Baseline in Average Diabetic Peripheral Neuropathy (DPN) Pain Score at Week 16 (Baseline, Week 16)Enrollment:73/73Sites: 48RANDOMIZED, DOUBLE, TREATMENT

Phase 3NegativeQ4 2010tacrolimusAtherosclerosis, Kidney FailureNCT00311311

Primary: Annual Change Rate in Total Plaque Volume (TPV) From Pre-conversion Baseline to 12 Months Post-transplant (Pre-conversion baseline and 12 months post-transplant)Enrollment:72/72Sites: 8RANDOMIZED, TREATMENT

Phase 3Q4 2010exemestaneBreast NeoplasmsNCT00143390

Primary: Time to Progression (TTP) - Expert Evaluation Committee Assessment (Up to 2008 days of the treatment)Enrollment:298/298Sites: 47RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q1 2011Neuralgia, Spinal Cord InjuriesNCT00407745

Primary: Duration Adjusted Average Change (DAAC) of Mean Pain Score (Baseline, Week 16)Enrollment:220/220Sites: 67RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q1 2011axitinibCarcinoma, Non-Small Cell LungNCT00768755

Primary: Progression-Free Survival (PFS) (Phase 2 baseline until the date of first documented progression or death due to any cause or initiation of subsequent anticancer therapy, assessed every 6 weeks up to 84 weeks)Enrollment:180/180Sites: 52RANDOMIZED, TREATMENT

Phase 3PositiveQ2 2011FibromyalgiaNCT00830167

Primary: Change From Baseline for Numerical Rating Scale (NRS) Pain Scores at Endpoint-LOCF (Last Observation Carried Forward) Relative to Baseline (Baseline, Week 15 or study discontinuation)Enrollment:498/498Sites: 35RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q2 2011AN2728 ointment, 2%PsoriasisNCT01300052

Primary: Percentage of Participants Who Achieved Success in Physician's Global Assessment (PGA) of Disease Severity at Day 84 (Day 84)Enrollment:68/68Sites: 10RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q4 2011Growth Hormone DeficiencyNCT01112865

Primary: Percentage of Dyads (Participant and Caregiver or Parent) and Adult Participants Reporting no Difference or Easier to Use for the New Genotropin Mark VII Injection Pen Compared to the Genotropin Pen® (Month 4)Enrollment:120/120Sites: 23RANDOMIZED, TREATMENT

Phase 2NegativeQ4 2011figitumumabSmall Cell Lung CarcinomaNCT00977561

Primary: Progression-Free Survival (PFS) (Baseline, every 2nd cycle (between Day 15-21, 1 cycle = 21 days) starting with Cycle 2 until disease progression, at the end of treatment visit (if more than 28 days have passed since last evaluation); and every 6 weeks until disease progression)Enrollment:9/9Sites: 51RANDOMIZED, TREATMENT

Phase 2NegativeQ4 2011SD-6010OsteoarthritisNCT00565812

Primary: Rate of Progression of Joint Space Narrowing (Baseline up to Month 24)Enrollment:1,457/1,457Sites: 183RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q4 2011Dexmedetomidine hydrochlorideSedationNCT01438957

Primary: Percentage of Patients Who Did Not Require Rescue Administration of Propofol to Achieve and Maintain Observer's Assessment of Alertness/Sedation (OAA/S) Score ≤4 During the Study Drug Administration. (Pre-dose, every 5 ± 2 minutes after start of study drug infusion and every 15 ± 2 minutes until 1 hour after study drug infusion. Before additional administration of sedative.)Enrollment:119/119Sites: 12RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q4 2011AG-013736Carcinoma, Non-Small-Cell Lung (NSCLC)NCT00735904

Primary: Percentage of Participants With Objective Response (OR) (Baseline until disease progression or discontinuation from the study due to any cause, assessed every 6 weeks during chemotherapy phase and every 8 weeks during single agent phase up to final study visit (Week 78))Enrollment:38/38Sites: 10NA, TREATMENT

Phase 2Q4 2011Tanezumab 10 mg IVNeoplasm Metastasis, Palliative CareNCT00545129

Primary: Change From Baseline in Daily Average Pain Intensity Numeric Rating Scale (NRS) Score at Week 6 (Baseline, Week 6)Enrollment:59/59Sites: 39RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2PositiveQ1 2012Inotuzumab Ozogamicin (CMC-544)LymphomaNCT00868608

Primary: Percentage of Participants With Indolent NHL Achieving CR or Partial Response (PR) According to International Response Criteria for NHL (Assessed for up to 2 years, including planned assessments every 8 to 12 weeks from first dose of study drug. Follow-up period may have been extended beyond 2 years due to dosing delays and allowed study visit windows.)Enrollment:81/81Sites: 42TREATMENT

Phase 3Q1 2012pregabalin (Lyrica)Diabetic Neuropathy, PainfulNCT01057693

Primary: Change From Single-Blind Baseline in Mean Pain Score at Week 19 During Double-Blind Phase (SB Baseline, Week 19 (DB Phase))Enrollment:633/633Sites: 172RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q1 2012Hypercholesterolemia, DyslipidemiaNCT01342211

Primary: Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Day 85 (Baseline, Day 85)Enrollment:93/93Sites: 44RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q1 2012DA-9501SedationNCT01438931

Primary: Incidence of patients who did not require rescue administration of propofol to achieve and maintain Observer's Assessment of Alertness/Sedation (OAA/S) Score ≤4 during the study drug administration (Pre-dose, every 5 ± 2 minutes during study drug infusion and every 15 ± 2 minutes until 1 hour after study drug infusion. Before additional administration of sedative.)Enrollment:162/162Sites: 18RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2NegativeQ1 2012PF-04531083Post-surgical Dental PainNCT01512160

Primary: Total Pain Relief (TOTPAR) Score From 0 to 6 Hours (0 to 6 hours)Enrollment:90/90Sites: 1RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q2 2012bevacizumabColorectal NeoplasmsNCT00460603

Primary: Percentage of Participants With Objective Response: Phase 2 (Baseline (Phase 2) until disease progression, assessed every 6 weeks up to Week 148 (Phase 2) or follow-up (every 6 weeks after last dose of study drug until progression or start of alternate therapy))Enrollment:187/187Sites: 106RANDOMIZED, TREATMENT

Phase 2NegativeQ2 2012PF-05089771Postoperative Dental PainNCT01529346

Primary: Total Pain Relief From 0 to 6 Hours (TOTPAR[6]) (0 to 6 hours)Enrollment:235/235Sites: 3RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q3 2012pegaptanib sodiumAnti- VGF Inhibitor, Diabetic Macular Edema, Diabetic RetinopathyNCT01189461

Primary: Incidence of Ocular and Non-Ocular Adverse Events (AEs) (Baseline up to 30 days after last dose)Enrollment:46/46Sites: 12NON_RANDOMIZED, TREATMENT

Phase 3NegativeQ3 2012Pain, PerioperativeNCT00905437

Primary: Mean Pain on Movement Score (Every 12 hours from Day 1 to Day 5 post-surgery)Enrollment:72/72Sites: 7RANDOMIZED, QUADRUPLE, SUPPORTIVE_CARE

Phase 3Q3 2012GenotropinIdiopathic Short StatureNCT00396097

Primary: Absolute On-target Difference (AOTD) at 24 Months (2 years)Enrollment:316/316Sites: 43RANDOMIZED, TREATMENT

Phase 2Q4 2012TasocitinibKeratoconjunctivitis SiccaNCT01226680

Primary: Change in length of wetting of Schirmer test strip without anesthesia from baseline (Week 12)0RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q4 2012etanerceptSpondylitis, AnkylosingNCT01258738

Primary: Percentage of Participants Achieving Ankylosing Spondylitis (ASAS) 40 Response at Week 12 (Week 12)Enrollment:225/225Sites: 50RANDOMIZED, TRIPLE, TREATMENT

Phase 3PositiveQ1 2013CP-690,550PsoriasisNCT01186744

Primary: Percentage of Participants Maintaining a Psoriasis Area and Severity Index 75 (PASI75) Response During the Double-Blind Treatment Withdrawal Period (Period B) (Weeks 4, 8 12, and 16 (Period B))Enrollment:666/666Sites: 87RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q1 2013Diabetes Mellitus, Type 2NCT01517373

Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1C) at Week 12 (Baseline (Day 1), Week 12)Enrollment:304/304Sites: 53RANDOMIZED, TRIPLE, TREATMENT

Phase 3PositiveQ1 2013CP-690,550Arthritis, RheumatoidNCT01039688

Primary: Modified Total Sharp Score (mTSS) at Month 6 (Month 6)Enrollment:956/956Sites: 176RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ2 2013CP-690,550PsoriasisNCT01276639

Primary: Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' at Week 16 (Week 16)Enrollment:901/901Sites: 74RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ4 2013treatmentNon Squamous Lung CancerNCT01154140

Primary: Progression-Free Survival (PFS) Based on IRR (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (up to 35 months))Enrollment:343/343Sites: 249RANDOMIZED, TREATMENT

Phase 2PositiveQ4 2013EnzalutamideProstate CancerNCT01547299

Primary: Pathologic Complete Response Rate (Day 180)Enrollment:52/52Sites: 4RANDOMIZED, TREATMENT

Phase 2NegativeQ4 2013PF-03049423Ischemic StrokeNCT01208233

Primary: Number of Participants With Any Abnormal Laboratory Test Results (Part 1* and 2) (Day 1 (Baseline) up to Day 90)Enrollment:181/181Sites: 70RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q1 2014MEK162BRAF or NRAS Mutant Metastatic MelanomaNCT01320085

Primary: Percentage of Participants With Objective Response (OR) (From date of randomization or date of start of treatment until date of first documentation of PD or death due to any cause, whichever occurred first (maximum duration of up to 33 months))Enrollment:183/183Sites: 25NON_RANDOMIZED, TREATMENT

Phase 2Q1 2014ACC-001 3 μg/ QS-21 50 μgAlzheimer's DiseaseNCT01227564

Primary: Change From Baseline in Brain Fibrillar Beta-Amyloid Protein (Aβ) at Week 104 as Measured by Standard Uptake Value Ratios (SUVRs) Over the Composite Regions of Interest (ROIs) (104 weeks)Enrollment:63/63Sites: 40RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ2 2014PregabalinDiabetic Neuropathy, PainfulNCT01332149

Primary: Baseline Mean Pain Score (Baseline)Enrollment:626/626Sites: 30RANDOMIZED, DOUBLE, TREATMENT

Phase 2PositiveQ2 2014PF-04171327Rheumatoid ArthritisNCT01393639

Primary: Percentage of Participants Achieving a 20% Improvement in American College of Rheumatology (ACR) Criteria at Week 8 (Week 8)Enrollment:323/323Sites: 93RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q4 2014PF-06473871Reduction of Hypertrophic Skin ScarringNCT01730339

Primary: Physician Global Assessment Using Physician Overall Opinion Question of Patient and Observer Scar Assessment Scale (POSAS) (Week 24)Enrollment:103/103Sites: 40RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q1 2015EnzalutamideAdvanced, Androgen Receptor Positive Triple Negative Breast CancerNCT01889238

Primary: Percentage of Participants With Clinical Benefit at Week 16: Evaluable Population (Week 16)Enrollment:118/118Sites: 132NA, TREATMENT

Phase 2Q2 2015PF-04691502Breast NeoplasmsNCT01658176

Primary: Progression-Free Survival (Baseline up to month 12)0RANDOMIZED, TREATMENT

Phase 2NegativeQ2 2015AEB071Uveal MelanomaNCT01801358

Primary: Phase Ib: Incidence of Dose Limiting Toxicities (DLT) During the First Cycle (Cycle 1 (up to 28 days))Enrollment:38/38Sites: 7RANDOMIZED, TREATMENT

Phase 2Jul 6, 2015SunitinibAdvanced Rare TumoursNCT01396408

Primary: Objective Response (Every 4 weeks)Enrollment:137/137Sites: 17NON_RANDOMIZED, TREATMENT

Phase 3Q4 2015DVS SRMajor Depressive DisorderNCT01371721

Primary: Percentage of Participants Experiencing a Treatment Emergent Adverse Event (Week 9 (B2061014)/Day 1 (B2061031) to Week 26 of the B2061031 Study)Enrollment:269/269Sites: 35TREATMENT

Phase 3PositiveQ1 2016PD-0332991Breast NeoplasmsNCT01740427

Primary: Progression-Free Survival (PFS) as Assessed by the Investigator (From randomization date to date of first documentation of progression or death (up to approximately 2.5 years))Enrollment:666/666Sites: 305RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3NegativeQ1 2016Bococizumab 150mgHyperlipidemiaNCT02458287

Primary: Percent Change From Baseline at Week 12 in Fasting Low Density Lipoprotein Cholesterol (LDL-C) Level for Bococizumab 150 mg Dose Group and Matched Placebo (Baseline, Week 12)Enrollment:299/299Sites: 30RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q1 2016PF-04236921Crohn's DiseaseNCT01345318

Primary: Number of Participants With On-Treatment Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), and Discontinuations Due to AEs (Baseline up to Week 48)Enrollment:191/191Sites: 127NON_RANDOMIZED, TREATMENT

Phase 3NegativeQ2 2016CP-690,550PsoriasisNCT01163253

Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) (Baseline up to 4 weeks after last dose of study drug (up to a maximum of 67 months))Enrollment:2,867/2,867Sites: 323NA, TREATMENT

Phase 3PositiveQ3 2016PF-05280014Metastatic Breast CancerNCT01989676

Primary: Objective Response Rate (ORR) Derived From Central Radiology Assessments: ITT Population (From the date of randomization until all participants had either completed the Week 33 tumor assessment or discontinued study drug earlier than the Week 33 visit)Enrollment:707/707Sites: 188RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q3 2016Staphylococcus aureus 4-antigen vaccineStaphylococcal InfectionsNCT02492958

Primary: Percentage of Participants With At Least 1 Local Reaction Within 14 Days of Vaccination (Day 1 up to Day 14)Enrollment:136/136Sites: 2RANDOMIZED, QUADRUPLE, OTHER

Phase 2PositiveQ1 2017Bivalent rLP2086 VaccineMENINGOCOCCAL INFECTIONNCT02531698

Primary: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >= Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Neisseria Meningitidis Serogroup B (MnB) Test Strains 1 Month After Vaccination 3 (1 month after Vaccination 3)Enrollment:400/400Sites: 15RANDOMIZED, TRIPLE, PREVENTION

Phase 3NegativeQ2 2017bococizumab (PF-04950615)Cardiovascular DiseaseNCT01975389

Primary: Event Rate Per 100 Participant-years for First Occurrence of Major Cardiovascular (CV) Event (From baseline until the date of first adjudicated and confirmed occurrence of major CV event (maximum duration: up to 3.4 years))Enrollment:10,564/10,564Sites: 1595RANDOMIZED, QUADRUPLE, PREVENTION

Phase 2Q3 2017rLP2086 vaccineMeningococcal B DiseaseNCT02534935

Phase 2Q4 2017Rheumatoid ArthritisNCT02969044

Primary: Change From Baseline in Simple Disease Activity Index (SDAI) Score at Week 8 (Baseline, Week 8)Enrollment:70/70Sites: 30RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q1 2018RimegepantMigraine, With or Without AuraNCT03237845

Primary: Percentage of Participants With Freedom From Pain at 2 Hours Post-dose (2 Hours post-dose)Enrollment:1,499/1,499Sites: 50RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q2 2018Moroctocog alfa (AF-CC)Hemophilia ANCT00543439

Primary: Mean Annualized Bleed Rate (ABR) by Treatment: On Demand Cohort (Day 1 up to Month 6 (OD Cohort, OD Therapy, Period 1); Month 7 up to Month 18 (OD Cohort, RP 25 IU/kg, Period 2))Enrollment:66/66Sites: 28RANDOMIZED, TREATMENT

Phase 2Q2 2018Crisaborole ointment 2% BIDDermatitis, AtopicNCT03233529

Primary: Change From Baseline in Lesion Total Sign Score (TSS) for Target Lesions Treated With Crisaborole Ointment 2% or Vehicle at Day 15 (Baseline (Day 1), Day 15)Enrollment:40/40Sites: 1RANDOMIZED, QUADRUPLE, BASIC_SCIENCE

Phase 2Q3 2018palbociclibSquamous Cell Carcinoma of the Head and Neck (SCCHN)NCT02499120

Primary: Overall Survival (OS) (Baseline up to primary completion date (PCD) (about 34 months))Enrollment:125/125Sites: 71RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q3 2018PF-06650833Rheumatoid ArthritisNCT02996500

Primary: Change From Baseline in the Simplified Disease Activity Index (SDAI) at Week 12 (Baseline and Week 12)Enrollment:269/269Sites: 103RANDOMIZED, TRIPLE, TREATMENT

Phase 3MixedQ3 2018avelumabOvarian CancerNCT02580058

Primary: Overall Survival (OS) (From randomization until the date of first documented progression or date of deaths from any cause, whichever came first, assessed up to 30 months (based on cutoff date: 19 September 2018).)Enrollment:566/566Sites: 295RANDOMIZED, TREATMENT

Phase 2Q1 2019Nonalcoholic Fatty Liver Disease, Nonalcoholic SteatohepatitisNCT03248882

Primary: Percent Change From Baseline in Liver Fat by Magnetic Resonance Imaging-Proton Density Fat Fraction (MRI- PDFF) at Week 16 (Baseline (between Day -14 and Day 1), Week 16)Enrollment:305/305Sites: 140RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q1 2019BosutinibLeukemia, Chronic MyelogenousNCT03128411

Primary: Percentage of Participants With Major Molecular Response (MMR) at Month 12 (Month 12)Enrollment:64/64Sites: 21NA, TREATMENT

Phase 3Q2 2019CelecoxibLow Back PainNCT02725411

Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) (Baseline (Day 1) up to 24 weeks after last dose of study drug (up to Week 80))Enrollment:277/277Sites: 55RANDOMIZED, DOUBLE, TREATMENT

Phase 3PositiveQ4 201920vPnCPneumococcal DiseaseNCT03828617

Primary: Percentage of Participants With Local Reactions Within 10 Days After Vaccination (Within 10 days after vaccination)Enrollment:1,710/1,710Sites: 21RANDOMIZED, DOUBLE, PREVENTION

Phase 3PositiveQ4 2019ZavegepantMigraineNCT03872453

Primary: Percentage of Participants With Freedom From Pain at 2 Hours Post-dose (2 hours post-dose)Enrollment:2,154/2,154Sites: 82RANDOMIZED, TRIPLE, TREATMENT

Phase 3NegativeQ4 2019AvelumabSquamous Cell Carcinoma of the Head and NeckNCT02952586

Primary: Progression-free Survival (PFS) Per Modified Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1) as Assessed by Investigator (From randomization until documented PD or death, censored date, whichever occurred first (up to 37 months))Enrollment:697/697Sites: 316RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ1 202013vPnCPneumococcal DiseaseNCT03835975

Primary: Percentage of Participants With Local Reactions Within 10 Days After Vaccination (Within 10 days after vaccination)Enrollment:875/875Sites: 42RANDOMIZED, PREVENTION

Phase 3PositiveQ1 2020LorlatinibCarcinoma, Non-Small-Cell LungNCT03052608

Primary: Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) Assessment (From time of Study Start up to 33 months)Enrollment:296/296Sites: 166RANDOMIZED, TREATMENT

Phase 3Q2 2020Atopic DermatitisNCT03796676

Primary: Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of 'Clear' (0) or 'Almost Clear' (1) and ≥2 Points Improvement From Baseline at Week 12 (Baseline to Week 12)Enrollment:287/287Sites: 136RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q2 2020PF-06700841Atopic DermatitisNCT03903822

Primary: Percent Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 6: Multiple Imputation (Baseline, Week 6)Enrollment:292/292Sites: 76RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Jun 1, 2020Neoadjuvant tamoxifen + goserelin (premenopausal women)Breast CancerNCT02624973

Primary: Predictive and prognostic value of mutations in 300 cancer-related genes assessed in breast cancer tissue by next generation sequencing before starting neoadjuvant therapy. (Ten years)Enrollment:200/200Sites: 7NON_RANDOMIZED, BASIC_SCIENCE

Phase 2Q2 2020TalazoparibOvarian CancerNCT02836028

Primary: Determine Objective Response Rate (ORR) (Anticipated in about 44 months following first patient enrolled)0RANDOMIZED, TREATMENT

Phase 3PositiveQ3 2020PalbociclibBreast NeoplasmsNCT02297438

Primary: Progression-Free Survival (PFS) Based on Investigator's Assessment: Up to Primary Completion Date (Randomization up to 65 months)Enrollment:340/340Sites: 54RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2PositiveQ3 2020TalazoparibProstate CancerNCT03148795

Primary: Best Objective Response Rate (ORR) (From first dose of study drug to best overall soft tissue response CR or PR (maximum duration of 25 months))Enrollment:128/128Sites: 120NA, TREATMENT

Phase 2NegativeQ3 2020TALAZOPARIBEarly Breast CancerNCT03499353

Primary: Percentage of Participants Achieving Pathological Complete Response (pCR) as Per Independent Central Review (ICR) in Evaluable Analysis Set as Per ICR With 80% Confidence Interval (CI) (Date of surgery (maximum of approximately 8 months post-baseline) (assessed within a maximum of 6 weeks of last dose of talazoparib))Enrollment:61/61Sites: 97NON_RANDOMIZED, TREATMENT

Phase 3Q4 2020PalbociclibBreast CancerNCT02513394

Primary: Invasive Disease Free Survival (iDFS) (4 years)Enrollment:5,796/5,796Sites: 437RANDOMIZED, TREATMENT

Phase 3Q1 2021etanerceptJuvenile Idiopahtic ArthritisNCT01421069

Primary: Number of Participants With Malignancy: All Periods of Parent and Extension Study (First dose of study medication in parent study up to 96 months in the extension study, for a maximum duration of 118 months (22 months of parent study and 96 months of extension study))Enrollment:109/109Sites: 35NA, TREATMENT

Phase 2Apr 13, 2021PD0332991Breast NeoplasmsNCT01723774

Primary: Number of Participants With Complete Cell Cycle Arrest at Cycle 1 Day 15 (PIK3CA Wild Type Cohort Only) (At cycle 1 day 15 (2 weeks))Enrollment:84/84Sites: 4NON_RANDOMIZED, TREATMENT

Phase 3PositiveQ4 2021RimegepantAcute MigraineNCT04574362

Primary: Percentage of Participants Who Had Freedom From Pain at 2 Hours Post-dose (2 hours post-dose)Enrollment:1,648/1,648Sites: 90RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Feb 15, 2022PalbociclibHead and Neck Squamous Cell CarcinomaNCT03389477

Primary: Tumor Response Rate of Newly Diagnosed p16INK4a Negative, HPV-unrelated HNSCC to Neoadjuvant Palbociclib Monotherapy (2 cycles (56 days))Enrollment:26/26Sites: 1NON_RANDOMIZED, TREATMENT

Phase 2Q1 2022LetrozoleBreast CancerNCT02764541

Primary: Difference in Anti-proliferative Activity of Patients Given Letrozole Versus Tamoxifen During the Window Phase (baseline to day 15)Enrollment:195/195Sites: 11RANDOMIZED, TREATMENT

Phase 2Q1 2022PF-06801591Advanced Malignancies, Non-small-cell Lung CancerNCT04181788

Primary: Phase 1b: Number of Participants With Dose-Limiting Toxicities (DLT) (Phase 1b: at the end of cycle 1 (28 days) for the PF-06801591 300 mg SC Q4W arms, and (42 days) for the PF-06801591 600 mg SC Q6W arms)Enrollment:155/155Sites: 49RANDOMIZED, TREATMENT

Phase 2Apr 29, 2022PalbociclibProstate CancerNCT02905318

Primary: Clinical benefit rate estimated by proportion of evaluable patients who had CR, PR or SD as their best response to treatment (36 months)Enrollment:19/19Sites: 7NA, TREATMENT

Phase 2Q2 2022Elranatamab (PF-06863135)Multiple MyelomaNCT04649359

Primary: Objective Response Rate (ORR) by Blinded Independent Central Review (BICR) as Per International Myeloma Working Group (IMWG) Criteria (From date of first dose until confirmed disease progression, death, start of new anticancer therapy, whichever occurred first (up to approximately 16 months))Enrollment:187/187Sites: 40NON_RANDOMIZED, TREATMENT

Phase 2NegativeQ3 2022TemanogrelRaynaud's Phenomenon Secondary to Systemic SclerosisNCT04915950

Primary: Change in Digital Blood Flow Based on Rewarming Area Under the Curve (AUC) During Thirty Minutes Following a Cold Challenge (30 minutes following a cold challenge)Enrollment:13/13Sites: 6RANDOMIZED, DOUBLE, TREATMENT

Phase 2Sep 30, 2022TanezumabSchwannomatosis, PainNCT04163419

Primary: Change in pain level (8 weeks)Enrollment:9/9Sites: 1RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q4 2022Talazoparib with enzalutamidem CRPCNCT03395197

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Occuring Within the First 66 Days of Dosing - Part 1 (Post dose on Day 1 up to Day 66 in Part 1)Enrollment:1,054/1,054Sites: 370RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q4 2022PF-06838435/ fidanacogene elaparvovecHemophilia BNCT03861273

Primary: Annualized Bleeding Rate (ABR) for Total Bleeds (Treated and Untreated) From Week 12 to Month 15 (Pre-infusion period: minimum of 6 months through first dose of current study, an average of 1.31 years (FIX Prophylaxis arm); Week 12 to Month 15 post infusion in current study (PF-06838435 arm))Enrollment:51/51Sites: 67NON_RANDOMIZED, TREATMENT

Phase 2NegativeQ4 2022RV521Respiratory Syncytial Virus (RSV), Lower Resp Tract InfectionNCT04225897

Primary: Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and TEAEs Leading to Permanent Discontinuation of IMP (From start of IMP on Day 1 up to Day 7)Enrollment:51/51Sites: 60RANDOMIZED, TRIPLE, TREATMENT

Phase 2Dec 31, 2022PalbociclibMetastatic Breast CancerNCT03147287

Primary: Progression-Free Survival (PFS), According to RECIST v1.1 Criteria (Investigator Assessment) (Tumor were assessed every 8 weeks until 24 weeks, then every 12 weeks. The median PFS follow-up time at database lock was 12.1 months (range 1 day to 50.1 months).)Enrollment:220/220Sites: 22RANDOMIZED, TREATMENT

Phase 3Q1 2023EnzalutamideHormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the ProstateNCT02319837

Primary: Metastasis-free Survival (MFS) Compared Between Enzalutamide Plus Leuprolide and Placebo Plus Leuprolide (From randomization until radiographic progression or death without radiographic progression, whichever occurred first (up to Month 98 when at least 197 MFS events occurred among the 3 treatment groups))Enrollment:1,068/1,068Sites: 255RANDOMIZED, TREATMENT

Phase 2Apr 7, 2023EnzalutamideProstate CancerNCT03809000

Primary: Percentage of Participants Alive Without Progression (Progression-Free Survival) (From randomization to first failure or last known follow-up. Median follow-up time at the time of analysis was 33.1 months. The 1- and 2-year estimates are reported.)Enrollment:188/188Sites: 108RANDOMIZED, TREATMENT

Phase 2May 1, 2023VinorelbineBreast CancerNCT03414658

Primary: Progression Free Survival (2 years)Enrollment:100/100Sites: 17RANDOMIZED, TREATMENT

Phase 2Q2 2023EtrasimodAlopecia AreataNCT04556734

Primary: Percent Change From Baseline in Severity of Alopecia Tool I (SALT I) at Week 24: DB Treatment Period (DB Treatment Period: Baseline (before dose on Day 1), Week 24)Enrollment:80/80Sites: 42RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q2 2023tucatinibHER2-positive Breast CancerNCT03975647

Primary: Progression-Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1 Based on Investigator Assessment (From the date of randomization to the date of PD or death from any cause or censoring date, whichever occurred first (maximum up to 43 months))Enrollment:466/466Sites: 490RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q3 2023TucatinibBreast CancerNCT04721977

Primary: Confirmed Objective Response Rate(cORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 Determined by Independent Central Review (ICR): Japanese Participants (From date of first dose until first documented disease progression or start of new anticancer therapy, whichever occurred first (maximum up to 17.8 months))Enrollment:66/66Sites: 28NA, TREATMENT

Phase 3PositiveQ3 2023tisotumab vedotinCervical CancerNCT04697628

Primary: Overall Survival (From randomization to date of death due to any cause or censoring date, whichever occurred first (maximum up to 25 months))Enrollment:502/502Sites: 211RANDOMIZED, TREATMENT

Phase 2Jul 28, 2023Talazoparib + AvelumabUrothelial CarcinomaNCT04678362

Primary: The progression-free survival (7 months)Enrollment:Target 50Sites: 14NA, TREATMENT

Phase 2Sep 26, 2023Gemtuzumab Ozogamicin (GO)Acute Myeloid LeukemiaNCT03374332

Primary: Phase 1: Determine the RP2D or MTD of Nonengraftment Donor Leukocyte Infusions With Fractionated Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML Defined as Dose Level Without Dose Limiting Toxicities. (35 days post infusion)Enrollment:11/11Sites: 1NON_RANDOMIZED, TREATMENT

Phase 2Q3 2023nirmatrelvirCOVID-19NCT05567952

Primary: Change From Baseline to Day 5 in Viral Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Ribonucleic Acid (RNA) Level in Nasopharyngeal (NP) Swabs: mITT Population (Baseline, Day 5)Enrollment:436/436Sites: 84RANDOMIZED, TRIPLE, TREATMENT

Phase 2PositiveQ4 2023EtrasimodUlcerative ColitisNCT05061446

Primary: Percentage of Participants Who Achieved Clinical Remission at Week 12 (Week 12)Enrollment:54/54Sites: 80RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q4 2023tucatinibUterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract NeoplasmsNCT04579380

Primary: Confirmed Objective Response Rate (cORR) as Assessed by Investigator (From the first dose of study treatment until the first documented CR or PR on or before the first documented PD or new anti-cancer therapies or death, whichever occurred first (up to 28.3 months))Enrollment:217/217Sites: 108NA, TREATMENT

Phase 2Nov 15, 2023AvelumabMetastatic Endometrial CancerNCT02912572

Primary: Objective Response Rate (Up to 39 months)Enrollment:106/106Sites: 4NON_RANDOMIZED, TREATMENT

Phase 2Dec 26, 2023LorlatinibAdvanced or Metastatic ROS1-Positive Non-Small Cell Lung CancerNCT05297890

Primary: Objective Response Rate (ORR) as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 per Independent Central Radiology (ICR) assessment (From the date of first dose of first subject to 6 months after the first dose of last subject, assessed up to approximately 19 months)Enrollment:70/70Sites: 31NA, TREATMENT

Phase 2Q1 2024Combination [RSVpreF+BNTb162b2]Healthy ParticipantsNCT05886777

Primary: Percentage of Participants With Local Reactions Within 7 Days After Vaccination (Day 1 to Day 7 after Vaccination on Day 1)Enrollment:1,142/1,142Sites: 37RANDOMIZED, TRIPLE, PREVENTION

Phase 3Q1 2024Quadrivalent influenza modRNA vaccineInfluenza, HumanNCT05540522

Primary: Percentage of Participants Reporting First Episode of LCI Cases With Associated Per-Protocol ILI Caused by Any Strain at Least 14 Days After Vaccination: 18-64 Years (Day 15 to surveillance cut-off (approximately 6 months))Enrollment:45,789/45,789Sites: 321RANDOMIZED, QUADRUPLE, PREVENTION

Phase 2Q1 2024ponsegromabNon-small Cell Lung Cancer, Pancreatic Cancer, Colorectal CancerNCT05546476

Primary: Part A: Change From Baseline in Body Weight at Week 12 (Baseline, Week 12)Enrollment:187/187Sites: 78RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2May 7, 2024Abrocitinib 200 mgGranuloma AnnulareNCT05650736

Primary: Percentage Change in BSA involvement by active GA (Baseline and 6 months)Enrollment:Target 10Sites: 1NA, TREATMENT

Phase 3Q2 2024Duchenne Muscular DystrophyNCT04281485

Primary: Change From Baseline in North Star Ambulatory Assessment (NSAA) Total Score at Week 52 (Baseline, Week 52)Enrollment:114/114Sites: 53RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q2 2024PF-07055480 (giroctocogene fitelparovec): Recombinant AAV2/6 Human Factor VIII Gene TherapyHemophilia ANCT04370054

Primary: Total Annualized Bleeding Rate (ABR) (FVIII Prophylaxis arm: a minimum of 7.4 months, up to maximum of 32.3 months (Pre-infusion period); PF-07055480 arm: Week 12 through at least 15 months of follow-up, maximum follow up was of 44.4 months (Post-infusion period))Enrollment:77/77Sites: 45NA, TREATMENT

Phase 3Jun 25, 2024PF-06651600Alopecia AreataNCT04006457

Primary: Main Study: Number of Participants With Treatment Emergent Adverse Events (TEAEs) Until Follow-up Visit (From start of study intervention (Day 1) until follow-up visit (4 weeks after last dose in Treatment period 1) (Up to Month 40))Enrollment:1,057/1,057Sites: 144NON_RANDOMIZED, TREATMENT

Phase 2Jun 30, 2024GlasdegibAcute Myelogenous Leukemia (AML) Due to Therapy, Acute Myeloid Leukemia With Myelodysplasia-Related ChangesNCT04231851

Primary: Percentage of Participants With Event-Free Survival at 6 Months (6 months)Enrollment:30/30Sites: 4NA, TREATMENT

Phase 2Q3 2024GedatolisibTNBC - Triple-Negative Breast CancerNCT03911973

Primary: Maximum Tolerated Dose (MTD) of talazoparib in combination with gedatolisib (Phase I) (28 days)Enrollment:Target 37Sites: 5NA, TREATMENT

Phase 2Q3 2024tucatinibColorectal Carcinoma, Gastric Adenocarcinoma, GEJ AdenocarcinomaNCT04430738

Primary: Number of Participants With Renal Dose-Limiting Toxicities (DLTs): Phase 1b (Cohort 1A and 1B) (From first dose of tucatinib until end of Cycle 3 (up to 42 days))Enrollment:40/40Sites: 27NON_RANDOMIZED, TREATMENT

Phase 2Q3 2024PalbociclibEwing Sarcoma, Solid Tumors, Rhabdoid TumorNCT03709680

Primary: Phase 2 open-label, randomized: Event-free survival (EFS) based on Investigator assessment. (Baseline to Month 24.)Enrollment:128/128Sites: 101RANDOMIZED, TREATMENT

Phase 2Sep 13, 2024ARV-471Breast CancerNCT04072952

Primary: Part A: Incidence of Dose Limiting Toxicities of ARV-471 (28 Days)Enrollment:217/217Sites: 16NON_RANDOMIZED, TREATMENT

Phase 2Q3 2024BNT162b2 (Omi XBB.1.5)/RIVInfluenza, Human, SARS-Co V-2 Infection, COVID-19NCT06237049

Primary: Percentage of Participants Who Reported Any Local Reaction up to 7 Days Following Vaccination (Day 1 to Day 7 following Vaccination on Day 1)Enrollment:644/644Sites: 30RANDOMIZED, SINGLE, PREVENTION

Phase 2Sep 18, 2024TG4001HPV-Related Carcinoma, HPV-Related Cervical Carcinoma, HPV-Related Anal Squamous Cell CarcinomaNCT03260023

Primary: Phase Ib: To Evaluate the Safety and Tolerability of the Combination of TG4001 Plus Avelumab in Participants With Recurrent or Metastatic HPV-16 Positive Advanced Malignancies (From Day 1 to Day 28)Enrollment:143/143Sites: 20RANDOMIZED, TREATMENT

Phase 3Oct 15, 2024palbociclibHER-2 Positive Breast Cancer, Estrogen Receptor Positive Breast CancerNCT02947685

Primary: Progression-free Survival (PFS) as Assessed by Investigator (7 years 3 months)Enrollment:518/518Sites: 106RANDOMIZED, TREATMENT

Phase 3Q4 2024PF-06801591Non-muscle Invasive Bladder CancerNCT04165317

Primary: Cohort A: Event Free Survival (EFS) as Assessed by the Investigator: Arm A Versus Arm C (From randomization (Day 1) to first documentation of high-grade disease, progression of disease, persistence of CIS or death due to any cause, whichever occurred first (maximum follow up duration was up to 257.1 weeks))Enrollment:1,068/1,068Sites: 194RANDOMIZED, TREATMENT

Phase 2Q4 2024CrizotinibNon-squamous Non-small-cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, ROS1 Gene RearrangementNCT04084717

Primary: Response Rate (5 years)Enrollment:33/33Sites: 1NON_RANDOMIZED, TREATMENT

Phase 3Q1 2025ARV-471Advanced Breast CancerNCT05654623

Primary: Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1- All Randomized Participants (From date of randomization to date of first documentation of objective PD or death (any cause) or censoring date, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively))Enrollment:624/624Sites: 312RANDOMIZED, TREATMENT

Phase 3Q1 2025TofacitinibJuvenile Idiopathic ArthritisNCT01500551

Primary: Number of Participants With Laboratory Test Abnormalities (During study treatment (maximum up to 118 months))Enrollment:302/302Sites: 104NA, TREATMENT

Phase 2NegativeQ1 2025Elranatamab + NirogacestatMultiple MyelomaNCT05090566

Phase 3Feb 28, 2025EtanerceptOligoarthritis, Juvenile, Polyarthritis, Juvenile, Rheumatoid Factor NegativeNCT03728478

Primary: Clinical remission on or off medication at 12 months (12 months)Enrollment:Target 260Sites: 1RANDOMIZED, TREATMENT

Phase 3Q2 2025PF-06741086Hemophilia A, Hemophilia BNCT03938792

Primary: Model-Based Annualized Bleeding Rate (ABR) of Treated Bleeding Events: Inhibitor Cohort (Participants With Prior OD Therapy at OP) (OP reporting group: Up to 6 months; ATP reporting group: up to 12 months)Enrollment:188/188Sites: 62NA, TREATMENT

Phase 3PositiveQ2 2025RSVpreF vaccineRespiratory Syncytial VirusNCT06325657

Primary: Percentage of Maternal Participants With Prespecified Local Reactions Within 7 Days After Vaccination (From Day 1 to Day 7 after vaccination)Enrollment:681/681Sites: 14RANDOMIZED, QUADRUPLE, PREVENTION

Phase 3Jun 16, 2025Tofacitinib 10mgGlioblastomaNCT05326464

Primary: Progression-free Survival (PFS) of the Study Cohort as Defined by RANO Criteria. (From treatment initiation until documented radiographic or clinical progression by RANO criteria or death, whichever came first, assessed up to 2 years.)Enrollment:18/18Sites: 1NON_RANDOMIZED, TREATMENT

Phase 2Q3 2025MET097Obesity, Overweight or ObesityNCT06712836

Phase 2Aug 1, 2025SasanlimabUrothelial Carcinoma BladderNCT05241340

Primary: Composite outcome for Feasibility and Safety (From date of registration to date of death due to any cause, assessed up to 4 weeks after radical cystectomy)Enrollment:Target 33Sites: 1NA, TREATMENT

Phase 2Q3 2025vepdegestrantBreast CancerNCT06206837

Primary: Phase 1b: Number of Participants With Dose Limiting Toxicities (28 days)Enrollment:71/71Sites: 58NA, TREATMENT

Phase 3Q3 2025TucatinibHER2 Positive Breast CancerNCT05132582

Primary: Progression-free survival (PFS) by investigator assessment per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (Up to approximately 3 years)Enrollment:654/654Sites: 307RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Sep 17, 2025VoxelotorSickle Cell DiseaseNCT06023199

Primary: Participant's Physical Performance Using 6 Minutes Walk Test (6MWT) Pre and Post Treatment with Voxelotor. (6 months from the treatment initiation)Enrollment:6/6Sites: 1NA, TREATMENT

Phase 3Q3 2025PalbociclibBreast NeoplasmsNCT03423199

Primary: Progression-free survival (PFS) (Baseline up to 3.5 years)Enrollment:Target 180Sites: 23RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q3 2025AZD4547Non-Small Cell Lung Cancer, Carcinoma, Squamous Cell, AdenocarcinomaNCT02664935

Primary: Objective response (OR) (From baseline until disease progression, assessed up to 18 months.)Enrollment:423/423Sites: 25NON_RANDOMIZED, TREATMENT

Phase 3Q4 2025EncorafenibNeoplasmsNCT04607421

Primary: SLI: Number of Participants With Dose Limiting Toxicity (DLTs) (Cycle 1 (28 days))Enrollment:841/841Sites: 272RANDOMIZED, TREATMENT

Phase 2Q4 2025MET097Obesity, Overweight or ObesityNCT06973720

Primary: Percent change from baseline in body weight at Week 28 (Baseline (Week 0) through Week 28 (Day 197))Enrollment:268/268Sites: 5RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q4 2025VLA15Lyme DiseaseNCT05477524

Primary: Relative incidence rate reduction of confirmed Lyme disease cases in the VLA15 group compared to the placebo group (Beginning 1 month after receiving the booster dose (28 days after receiving the booster dose through the end of the Lyme disease season following the booster dose (end of October)).)Enrollment:12,546/12,546Sites: 129RANDOMIZED, QUADRUPLE, PREVENTION

Phase 2Dec 31, 2025RitlecitinibCeliac DiseaseNCT05636293

Primary: Change in Small Intestinal Histology based on Vh:Cd ratio (Through study completion, average of 1 year.)Enrollment:62/62Sites: 1RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q4 2025Irinotecan + CarboplatinMetastatic Breast CancerNCT00248287

Primary: Objective Response Rates (ORR) (2 years)Enrollment:154/154Sites: 59RANDOMIZED, TREATMENT

Phase 3Q4 2025SasanlimabNSCLCNCT06218069

Primary: Number of participants with successful completion of curative surgery within 42 days after start of subcutaneous sasanlimab as neo-adjuvant treatment. (2 years)Enrollment:Target 20Sites: 2NON_RANDOMIZED, TREATMENT

Phase 2Dec 31, 2025OnivydeRecurrent Solid Tumor, Recurrent Ewing Sarcoma, Recurrent HepatoblastomaNCT04901702

Primary: Phase I:To determine the recommended phase 2 doses (RP2Ds) of Onivyde combined with talazoparib (Arm A) and Onivyde combined with temozolomide (Arm B) administered to children, adolescents and young adults with refractory or recurrent solid malignancies. (approximately 21 days)Enrollment:Target 90Sites: 10RANDOMIZED, TREATMENT

Phase 2Jan 2, 2026MET097 InjectionObesity in Diabetes, Type 2 Diabetes Mellitus (T2DM)NCT06897202

Primary: Percent change from baseline in body weight at Week 28 (Day 197) (Baseline (Week 0) through Week 28 (Day 197))Enrollment:133/133Sites: 29RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q1 2026EncorafenibMelanomaNCT04657991

Primary: Safety Lead In (SLI): Incidence of Dose Limiting Toxicities (DLTs) (First 2 Cycles of Treatment (cycles are 21 days))Enrollment:257/257Sites: 151RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q1 2026Brentuximab vedotinDiffuse Large B-cell LymphomaNCT04404283

Primary: Overall survival (OS) (Approximately 2 years)Enrollment:239/239Sites: 143RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q1 2026PF-07220060 CDK4 inhibitorAdvanced or Metastatic Breast CancerNCT06105632

Primary: Progression-Free Survival (PFS) progression, as determined by investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (From Initiation up to 2 years)Enrollment:333/333Sites: 48RANDOMIZED, TREATMENT

Phase 3Jan 27, 2026Palbociclib 125mgBreast Cancer RecurrentNCT03820830

Primary: Duration of invasive disease free survival of all randomized participants. (Assessed from the date treatment starts until the date of first documented invasive local, regional or distant recurrence, a second invasive cancer or death, or until approximately 4 years after treatment stops.)Enrollment:405/405Sites: 53RANDOMIZED, TREATMENT

Phase 3Feb 1, 2026KetamineChronic Daily HeadacheNCT05306899

Primary: Difference in headache days between the 2 groups (At 4 weeks)Enrollment:Target 56Sites: 2RANDOMIZED, DOUBLE, TREATMENT

Phase 2NegativeQ1 2026encorafenibMelanomaNCT05926960

Primary: Objective Response Rate (ORR) is defined as the proportion of participants in each treatment arm with a confirmed best overall response of either Complete Response (CR) or Partial Response (PR), as determined by investigator assessment per RECIST v1.1 (Time from the date of randomization to the earliest date disease progression, or start of subsequent anticancer therapy, or death due to any cause (assessed up to approximately 48 months).)Enrollment:38/38Sites: 24RANDOMIZED, TREATMENT

Phase 2Q1 2026brentuximab vedotinMelanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and NeckNCT04609566

Phase 2Feb 14, 2026Brentuximab vedotinDiffuse Cutaneous Systemic SclerosisNCT05149768

Primary: Change in skin thickness measured by modified Rodnan Skin Score (48 weeks)Enrollment:Target 11Sites: 1NA, TREATMENT

Phase 3Feb 15, 202640 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetateEndometriosisNCT06439524

Primary: This study aims to determine if immediate postoperative medical suppression with Regugolix combination therapy (Rel-CT) following excisional surgery for endometriosis is superior to surgery alone. (6 months)Enrollment:Target 110Sites: 1RANDOMIZED, TREATMENT

Phase 3Q1 2026talazoparib plus enzalutamideProstate CancerNCT04821622

Primary: radiological Progression-Free Survival (randomization up to 3 years)Enrollment:599/599Sites: 313RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q1 2026sigvotatug vedotinCarcinoma, Non-Small-Cell LungNCT06012435

Primary: Overall survival (OS) between the experimental arm (sigvotatug vedotin) and control arm (docetaxel) (Approximately 5 years)Enrollment:762/762Sites: 331RANDOMIZED, TREATMENT

Phase 2Q1 2026tisotumab vedotinColorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic CancerNCT03485209

Primary: Confirmed Objective Response Rate (ORR) (Parts A, B, C, D, E, F, and G) (Up to approximately 3 years)Enrollment:350/350Sites: 175NON_RANDOMIZED, TREATMENT

Phase 2Mar 30, 2026PalbociclibMantle Cell Lymphoma, B Cell LymphomaNCT03478514

Primary: Progression free survival (42 months)Enrollment:39/39Sites: 9NA, TREATMENT

Phase 2Mar 30, 2026AbrocitinibPost-COVID Condition, Fatigue SymptomNCT06597396

Primary: Change from baseline in mean score for FACIT (Functional Assessment of Chronic Illness Therapy) Fatigue Scale (Baseline to Day 84)Enrollment:46/46Sites: 1RANDOMIZED, TRIPLE, TREATMENT

Phase 2NegativeMar 31, 2026Tisotumab VedotinCervical CancerNCT03786081

Primary: Dose escalation: Dose Limiting Toxicities (DLTs) (DLTs will be identified during the first treatment cycle (21 day cycles))Enrollment:214/214Sites: 71NON_RANDOMIZED, TREATMENT

Phase 2Mar 31, 2026DacomitinibNSCLC Stage IIIB, NSCLC Stage IIIC, NSCLC Stage IVNCT04027647

Primary: Progression-Free Survival (PFS) (From the start of treatment to the date of disease progression or death due to any cause at 12 months)Enrollment:118/118Sites: 9NA, TREATMENT

Phase 2Q1 2026TalazoparibBreast CancerNCT03964532

Primary: Quantification of Grade 3 and 4 toxicities (Adverse Events) (from the start of study drugs through 30 days after end of treatment (approximately 1 year))Enrollment:24/24Sites: 2NA, TREATMENT

Phase 2Apr 1, 2026AxitinibMetastatic Renal Cell CarcinomaNCT05817903

Primary: Efficacy of axitinib in addition to nivolumab compared to nivolumab alone at the end of the induction with nivolumab plus ipilimumab in mRCC. (From date of randomization until the date of first documented progression or date of death from any cause, whichever came first)Enrollment:Target 118Sites: 23RANDOMIZED, TREATMENT

Phase 3Q2 2026tucatinibColorectal NeoplasmsNCT05253651

Primary: Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) by Blinded Independent Central Review (BICR) (Up to approximately 3 years)Enrollment:Target 400Sites: 366RANDOMIZED, TREATMENT

Phase 2NegativeQ2 2026maplirpacept (PF-07901801)Diffuse Large B-Cell LymphomaNCT05896163

Primary: Phase 1b: Number of participants with Dose limiting toxicities (DLT) (21 days following first PF-07901801 dose)Enrollment:40/40Sites: 10RANDOMIZED, TREATMENT

Phase 2Q2 2026MET233Obesity and OverweightNCT07022977

Primary: Occurrence of Treatment Emergent Adverse Events (Part A (Baseline to Day 85), Part B (Baseline to Day 113), Part C (Baseline to Day 162), Part D (Baseline to Day 239))Enrollment:144/144Sites: 1RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Apr 17, 2026DexmedetomidineDelirium, Critical Illness, Sedation ComplicationNCT04801589

Primary: Daily prevalence of delirium (14 days)Enrollment:Target 372Sites: 1RANDOMIZED, QUADRUPLE, PREVENTION

Phase 3Q2 2026ElranatamabMultiple MyelomaNCT05020236

Primary: Part 1 Safety Lead-In: Incidence of dose limiting toxicities (First 42 days after first elranatamab dose)Enrollment:Target 893Sites: 237RANDOMIZED, TREATMENT

Phase 2Q2 2026TrastuzumabBrain Metastases, Human Epidermal Growth Factor 2 Positive Carcinoma of Breast, Advanced Breast CancerNCT05323955

Primary: Progression Free Survival (PFS) (3 years)Enrollment:Target 48Sites: 8NA, TREATMENT

Phase 2Q2 2026vepdegestrantBreast CancerNCT06125522

Primary: Phase 1b: Number of Participants With Dose Limiting Toxicities (28 days)Enrollment:11/11Sites: 21NA, TREATMENT

Phase 3May 5, 2026BNT162b2 (2025/2026 recommended SARS-CoV-2 strain)COVID-19, SARS-COV-2 InfectionNCT07069309

Primary: Percentage of participants reporting local reactions (For up to 7 days after vaccination)Enrollment:774/774Sites: 19NA, PREVENTION

Phase 2Q2 2026Multivalent Pneumococcal Vaccine - Formulation 1Pneumococcal DiseaseNCT06182124

Phase 2Q2 2026disitamab vedotinCarcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Endometrial NeoplasmsNCT06003231

Primary: Confirmed Objective Response Rate (ORR) per Response Evaluation in Solid Tumors version 1.1 (RECIST v1.1) by investigator assessment (Approximately 3 years)Enrollment:120/120Sites: 96NA, TREATMENT

Phase 2Q2 2026EncorafenibMetastatic Colorectal CancerNCT05217446

Primary: Progression-free Survival (PFS) (Duration of study, approximately 45 months)Enrollment:108/108Sites: 59RANDOMIZED, TREATMENT

Phase 3Jun 16, 2026Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram doseSARS-Co V-2 Virus, Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19NCT05543616

Primary: Substudy A (SSA) - Ph 1 dose finding, percentage of participants reporting local reactions (for up to 7 days following Dose 1, Dose 2, Dose 3 and Dose 4)Enrollment:4,338/4,338Sites: 96NON_RANDOMIZED, PREVENTION

Phase 2Jun 30, 2026Anti-OX40 Antibody PF-04518600Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast CancerNCT03971409

Primary: Best Overall Response Rate (BORR) (From treatment initiation until disease progression, an estimated average of 1 year)Enrollment:145/145Sites: 12RANDOMIZED, TREATMENT

Phase 3Q2 2026disitamab vedotinUrothelial CarcinomaNCT05911295

Primary: Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) by blinded independent central review (BICR) (Approximately 3 years)Enrollment:412/412Sites: 268RANDOMIZED, TREATMENT

Phase 2Jun 30, 2026PalbociclibBreast Cancer Stage II, Breast Cancer Stage IIINCT03609047

Primary: distant recurrence-free interval (D-RFI) rate (5 years after first patient inclusion)Enrollment:Target 366Sites: 73RANDOMIZED, TREATMENT

Phase 2Q2 2026TalazoparibBreast CancerNCT04039230

Primary: Dose Limiting Toxicity (2 years)Enrollment:Target 75Sites: 3NA, TREATMENT

Phase 2Jun 30, 2026Abrocitinib 200 MG Oral TabletDiabetes Mellitus, Type 1NCT05743244

Primary: The area under the stimulated C-peptide curve (Y_AUC) (12 Months)Enrollment:Target 78Sites: 30RANDOMIZED, TRIPLE, TREATMENT

Phase 2Jun 30, 2026anastrozoleFemale Breast Carcinoma, Breast CancerNCT02942355

Primary: Number of participants with neutropenia that leads to permanent treatment discontinuation (From enrollment to treatment discontinuation; participants remain on treatment until disease progression, unacceptable toxicity, participant withdrawal, or investigator decision. Assessed for approximately 4 years.)Enrollment:Target 40Sites: 1NON_RANDOMIZED, TREATMENT

Phase 2Q2 2026PalbociclibMetastatic Breast CancerNCT02738866

Primary: Progression-free survival (6 months)Enrollment:60/60Sites: 5NA, TREATMENT

Phase 3Q3 2026PF-06821497Metastatic Castrate Resistant Prostate Cancer (m CRPC)NCT06551324

Primary: Radiographic Progression Free Survival (rPFS) assessed by blinded independent central review (BICR) per RECIST v1.1 and Prostate Cancer Clinical Trials Working Group 3 (PCWG3) (Randomization up to approximately 2 years.)Enrollment:Target 600Sites: 224RANDOMIZED, TREATMENT

Phase 3Q3 2026nirmatrelvirCOVID-19NCT05261139

Primary: Cohort 1-2: Maximum Observed Plasma Concentration (Cmax) of nirmatrelvir and ritonavir (Day 1: 1 hour-post dose; Day 4: pre-dose; Day 5: pre-dose, and 1, and 2 hours post dose)Enrollment:Target 160Sites: 73NON_RANDOMIZED, TREATMENT

Phase 3Jul 31, 2026BNT162b2 (2025/2026 formulation)COVID-19, SARS-COV-2 InfectionNCT07222384

Primary: Percentage of participants reporting local reactions (For up to 7 days after vaccination)Enrollment:344/344Sites: 29NA, PREVENTION

Phase 3Jul 31, 2026BNT162b2 VaccineCOVID-19, SARS-COV-2 InfectionNCT07300839

Primary: Percentage of participants reporting local reactions or systemic events (From Day 1 up to 7 days after Vaccination)Enrollment:5,240/5,240Sites: 196RANDOMIZED, QUADRUPLE, PREVENTION

Phase 2Aug 1, 2026ElranatamabRefractory Multiple Myeloma, Relapse Multiple Myeloma, Multiple MyelomaNCT06138275

Primary: Complete Response (CR) rate or stringent CR (sCR) post consolidation therapy (The time from start of treatment to first date that progressive disease is objectively documented or death due to any cause, for up to 5 years. Participants without events reported are censored at the last disease evaluation.)Enrollment:Target 32Sites: 3NA, TREATMENT

Phase 2Q3 2026ATM-AVIGram-negative Bacterial InfectionsNCT05639647

Primary: Maximum Predicted Plasma Concentration (Cmax) of ATM and AVI (Up to 15 Days)Enrollment:Target 48Sites: 23RANDOMIZED, SINGLE, TREATMENT

Phase 2Aug 20, 2026IpilimumabMelanomaNCT04996823

Primary: Overall Response Rate (Up to 24 months)Enrollment:Target 24Sites: 1NA, TREATMENT

Phase 2Q3 2026PF-07220060 + PF-07104091 combination dose escalationBreast Cancer, Solid TumorsNCT05262400

Primary: Dose Escalation: Number of participants with Dose-limiting toxicities (DLT) during first cycle (Cycle 1 (28 days))Enrollment:235/235Sites: 44NON_RANDOMIZED, TREATMENT

Phase 3Q3 2026ElranatamabMultiple MyelomaNCT06152575

Primary: Progression free survival per International Myeloma Working Group criteria (Up to approximately 5 years)Enrollment:Target 492Sites: 270RANDOMIZED, TREATMENT

Phase 3Q3 2026RSVpreFRespiratory Syncytial Virus (RSV)NCT07543380

Primary: Percentage of participants reporting prompted local reactions within 7 days following investigational product administration (Day 7)Enrollment:130/130Sites: 5NA, PREVENTION

Phase 2Aug 31, 2026TalazoparibBreast CancerNCT03990896

Primary: Median Progression Free Survival (From the start of treatment until death or disease progression, up to approximately 2 years)Enrollment:Target 30Sites: 7NA, TREATMENT

Phase 2Sep 1, 2026PalbociclibMetastatic Malignant Neoplasm to Brain, Recurrent Brain Metastases, Progressive Brain MetastasesNCT02896335

Primary: Intracranial Clinical Benefit Rate (Cohort 1) (8 weeks (Screening through 8 weeks))Enrollment:Target 45Sites: 2NON_RANDOMIZED, TREATMENT

Phase 2Q3 2026ARV-471Breast CancerNCT05548127

Primary: Phase 1b: number of participants with dose limiting toxicities (28 days)Enrollment:37/37Sites: 37NA, TREATMENT

Phase 2Q3 2026PF-07868489Pulmonary Arterial HypertensionNCT06137742

Primary: Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) (Baseline up to Day 113.)Enrollment:97/97Sites: 46RANDOMIZED, QUADRUPLE, BASIC_SCIENCE

Phase 2Q3 2026MET233 and MET097Obesity and Obesity-related Medical ConditionsNCT06924320

Primary: Occurrence of treatment-emergent adverse events (TEAEs) (Part A (Baseline, Day 85), Part B (Baseline, Day 155), Part C (Baseline, Day 155), Part D (Baseline, Day 218), Part E (Baseline, Day 246), Part G (Baseline, Day 274))Enrollment:Target 381Sites: 1RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q3 2026PF-07220060Liposarcoma, Prostate Cancer, Breast NeoplasmsNCT04557449

Primary: Number of participants with dose limiting toxicities in the Dose Escalation Portion (Baseline up to day 28 of Cycle 1.)Enrollment:362/362Sites: 39NON_RANDOMIZED, TREATMENT

Phase 2Q3 2026Ipatasertib 300mgMetastatic Breast Cancer, ER+ Breast Cancer, Advanced Breast CancerNCT04920708

Primary: Assess progression free survival (PFS) (Time from date of randomisation until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 51 months)Enrollment:57/57Sites: 13RANDOMIZED, TREATMENT

Phase 3Q3 2026AvelumabAdvanced Malignancies, NSCLC, Ovarian CancerNCT05059522

Primary: Number of participants with adverse events leading to permanent discontinuation of study intervention (Baseline up to approximately 5 years)Enrollment:77/77Sites: 71NON_RANDOMIZED, TREATMENT

Phase 2Sep 30, 2026AvelumabBreast CancerNCT03573648

Primary: Clinical Complete Response (2 years)Enrollment:33/33Sites: 4RANDOMIZED, TREATMENT

Phase 2Oct 1, 2026Atezolizumab - 28 Day CycleEndometrial CancerNCT04486352

Primary: Investigator-assessed overall response rate (ORR) of each biomarker cohort (48 Months)Enrollment:Target 148Sites: 21NON_RANDOMIZED, TREATMENT

Phase 2Oct 1, 2026SasanlimabMetastatic Renal Cell Carcinoma, Metastatic Renal Cancer, Renal Cell CarcinomaNCT07123090

Primary: Objective Response Rate (ORR) (Disease assessment will be performed every 8 weeks for the first 16 weeks, then every 12 weeks on treatment for up to 14 months)Enrollment:Target 25Sites: 2NA, TREATMENT

Phase 2Oct 1, 2026TalazoparibRecurrent Extensive Stage Small Cell Lung Carcinoma, Refractory Extensive Stage Small Cell Lung CarcinomaNCT03672773

Primary: Objective response rate defined as the proportion of participants with a confirmed complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIS)T 1.1 (Up to 1 year)Enrollment:35/35Sites: 6NA, TREATMENT

Phase 3Q4 2026RimegepantMigraineNCT06616194

Primary: Number of migraine days per month (12 Weeks)Enrollment:Target 200Sites: 102RANDOMIZED, QUADRUPLE, PREVENTION

Phase 2Q4 2026PF-07275315Atopic DermatitisNCT05995964

Primary: The number of participants achieving ≥75% improvement in EAS175 from baseline at week16. (Week 16)Enrollment:Target 340Sites: 98RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q4 2026RimegepantMenstrual MigraineNCT06641466

Primary: Mean change from the Observation Period in number of migraine days per 5-day perimenstrual period across each cycle of the Double-Blind Treatment Phase (5 months (5 menstrual cycles))Enrollment:Target 723Sites: 123RANDOMIZED, QUADRUPLE, PREVENTION

Phase 2Q4 2026PalbociclibMetastatic Breast Cancer (MBC)NCT02605486

Primary: recommended phase II dose (RP2D) (phase I) (1 year)Enrollment:46/46Sites: 5NA, TREATMENT

Phase 2Q4 2026OnvansertibMetastatic Colorectal Cancer, CRC, KRAS/NRAS MutationNCT06106308

Primary: Objective Response Rate (ORR) (Up to approximately 1 year)Enrollment:110/110Sites: 41RANDOMIZED, TREATMENT

Phase 2Dec 1, 2026ElranatamabMultiple MyelomaNCT06015542

Primary: Evaluate the safety of self-administration of Elranatamab in the patients' own homes assessed by checklist (approximately 24 weeks)Enrollment:Target 20Sites: 2NA, TREATMENT

Phase 2Dec 1, 2026elranatamabRelapsed Refractory Multiple Myeloma (RRMM), Relapsed Refractory Multiple MyelomaNCT06832865

Primary: Objective response rate (ORR) (Day 1 to 2 years post-treatment.)Enrollment:Target 30Sites: 3NA, TREATMENT

Phase 3Q4 2026PF-06821497Metastatic Castration-Resistant Prostate CancerNCT06629779

Primary: Radiographic Progression Free Survival (rPFS) (Randomization up to approximately 3 years)Enrollment:Target 900Sites: 233RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q4 2026Ritlecitinib higher doseSevere Alopecia AreataNCT07029711

Primary: For US and Countries Following US Analysis Plan: Response based on achieving an absolute Severity of Alopecia Tool (SALT) score ≤20. (Week 24)Enrollment:208/208Sites: 83RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q4 2026VLA15Lyme DiseaseNCT07500506

Primary: Percentage of participants reporting prespecified local reactions (Within 7 days following each study intervention administration)Enrollment:Target 1,712Sites: 22RANDOMIZED, TRIPLE, PREVENTION

Phase 2Dec 4, 2026SunitinibRenal Cell CarcinomaNCT00715442

Primary: Time to progression (TTP) (Baseline start of treatment to disease progression; up to 5 years)Enrollment:50/50Sites: 2NA, TREATMENT

Phase 2Q4 2026disitamab vedotinUrothelial CarcinomaNCT04879329

Primary: Confirmed Objective Response Rate (cORR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1) by blinded independent central review (BICR) (Cohorts A, B, C, and G) (Duration of treatment; approximately 2 years)Enrollment:Target 372Sites: 221RANDOMIZED, TREATMENT

Phase 2Q4 2026Ritlecitinib 50 mgChronic Spontaneous UrticariaNCT07219615

Primary: Change from baseline in Urticaria Activity Score 7 (UAS7) at Week 12 (Week 12)Enrollment:Target 200Sites: 69RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q4 2026ARV-471Breast CancerNCT05573555

Primary: Phase 1b: Number of Participants With Dose Limiting Toxicities (Cycle 1 (28 days))Enrollment:20/20Sites: 29NA, TREATMENT

Phase 3Q4 2026Vepdegestrant (ARV-471/PF-07850327)Breast CancerNCT05909397

Primary: Study Lead-in (SLI): Incidence of Grade 4 neutropenia (From randomization date up to Cycle 4 (each cycle is 28 days).)Enrollment:59/59Sites: 29RANDOMIZED, TREATMENT

Phase 2Dec 31, 2026OlaparibLymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid TumorsNCT03297606

Primary: Objective response rate defined as the number of patients with complete response or partial response (4 years)Enrollment:Target 720Sites: 10NON_RANDOMIZED, TREATMENT

Phase 2Q4 2026PalbociclibBreast Cancer, Head and Neck CancerNCT05226871

Primary: Number/Percentage of Participants with Treatment-Emergent Adverse Events (AEs) Leading to Permanent Discontinuation of Study Treatment and Serious Adverse Events (SAEs) (Baseline up to 28 days after last dose of study intervention)Enrollment:35/35Sites: 23NON_RANDOMIZED, TREATMENT

Phase 2Q4 2026Elranatamab injectionRefractory Multiple MyelomaNCT06421675

Primary: Hospitalization rate (2 weeks)Enrollment:Target 40Sites: 6NA, TREATMENT

Phase 2Dec 31, 2026Gemtuzumab OzogamicinAcute Myeloid LeukemiaNCT03737955

Primary: Clinical response rate (Up to 70 days)Enrollment:Target 36Sites: 1NA, TREATMENT

Phase 2Dec 31, 2026GemcitabineHodgkin LymphomaNCT05180097

Primary: Complete response rate by PET Deauville criteria (score 1-3) of pembrolizumab and brentuximab vedotin compared to standard GDP (gemcitabine, dexamethasone, cisplatin) given as salvage therapy (52 months)Enrollment:Target 84Sites: 18RANDOMIZED, TREATMENT

Phase 2Dec 31, 2026Tucatinib 150 MGHER2-positive Breast Cancer, LMDNCT06016387

Primary: Survival status from the start of XRT (From date of baseline until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months)Enrollment:Target 30Sites: 2NA, TREATMENT

Phase 2Q4 2026PF-07104091 monotherapy dose escalationSmall Cell Lung Cancer, Ovarian Cancer, Breast CancerNCT04553133

Primary: Dose Escalation: Number of participants with Dose-limiting toxicities (DLT) during first cycle (28 days)Enrollment:157/157Sites: 22NON_RANDOMIZED, TREATMENT

Phase 2Dec 31, 2026SunitinibCiliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Iris MelanomaNCT02068586

Primary: Overall survival (Cohort 1) (Time of definitive treatment of the primary tumor until death from any cause, assessed at 2 years)Enrollment:Target 210Sites: 1RANDOMIZED, TREATMENT

Phase 3Q1 2027RSVpreFLower Respiratory Tract IllnessNCT05035212

Primary: Efficacy Study: Number of first episode of RSV-associated lower respiratory tract illness (LRTI-RSV) in the first RSV season (From Day 15 after vaccination until the end of season 1 visit (an average of 6 months))Enrollment:38,861/38,861Sites: 263RANDOMIZED, TRIPLE, PREVENTION

Phase 2Jan 30, 2027Brentuximab vedotinMycosis FungoidesNCT05357794

Primary: To establish the overall response rate (ORR) (through study completion, an average of 1 year)Enrollment:Target 30Sites: 1NA, TREATMENT

Phase 2Q1 2027BinimetinibMetastatic Uveal MelanomaNCT05170334

Primary: Overall Response Rate (Up to 5 years)Enrollment:7/7Sites: 1NA, TREATMENT

Phase 2Q1 2027AxitinibPheochromocytoma, ParagangliomaNCT03839498

Primary: Response Rate (RR) (Up to 16 weeks)Enrollment:6/6Sites: 1NA, TREATMENT

Phase 2Q1 2027RitlecitinibHidradenitis SuppurativaNCT07228390

Primary: Difference in proportion of responders based on Hidradenitis Suppurativa Clinical Response achieving at least 50% reduction from baseline (Hidradenitis Suppurativa Clinical Response HiSCR50) in patients with HS treated with ritlecitinib versus placebo. (Week 16)Enrollment:128/128Sites: 67RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q1 2027PF-07275315AsthmaNCT06977581

Primary: Change from baseline in pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 12 (Week 12)Enrollment:Target 252Sites: 137RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q1 2027RitlecitinibVitiligoNCT06163326

Primary: Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events (AEs) leading to discontinuation (Screening up to at least 30 days after last dose of study drug (week 52 or Early Termination))Enrollment:394/394Sites: 73RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q2 2027tofacitinibUlcerative ColitisNCT04624230

Primary: Remission by central read Mayo score following 44 weeks in the maintenance phase. (Outcome measured at the end of the 44 weeks of the maintenance phase.)Enrollment:118/118Sites: 69NA, TREATMENT

Phase 2Q2 2027Part A: ATM-AVI Single Dose, Cohorts 1-4Gram-negative Bacterial InfectionNCT06462235

Primary: Maximum Predicted Plasma Concentration (Cmax) of ATM and AVI (Up to Day 15)Enrollment:Target 48Sites: 30NON_RANDOMIZED, BASIC_SCIENCE

Phase 2Q2 2027MODULE: conventional chemotherapy (Cytarabine+Daunorubicin) in combination with midostaurin+GOAcute Myeloid LeukemiaNCT04385290

Primary: Maximum tolerated dose (MTD) of midostaurin and GO combination (treatment day 8 until day 42 at the latest)Enrollment:Target 214Sites: 21RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q2 2027PG4Pneumococcal DiseaseNCT06524414

Primary: Percentage of participants reporting local reactions within 7 days after each dose (Day 7)Enrollment:605/605Sites: 68RANDOMIZED, QUADRUPLE, PREVENTION

Phase 3Q2 2027AbrocitinibEczemaNCT06807268

Phase 2Q2 2027Nivolumab and/or IpilimumabMucosal MelanomaNCT05384496

Phase 2May 31, 2027DelamanidTuberculosis, Multidrug-ResistantNCT03828201

Phase 2Q2 2027Vaccine Candidate #1Healthy AdultsNCT07431853

Phase 2Jul 1, 2027RelugolixProstate Cancer, Prostatic NeoplasmsNCT05765500

Phase 3Q3 2027PF-07248144Breast CancerNCT07062965

Phase 3Q3 2027PF-06823859MyositisNCT05895786

Phase 3Q3 2027RitlecitinibStable Nonsegmental Vitiligo, Active Nonsegmental VitiligoNCT06072183

Phase 2Q3 2027ElranatamabSmoldering Multiple MyelomaNCT06183489

Phase 2Q3 2027HCQBreast CancerNCT04841148

Phase 3Q3 2027ElranatamabMultiple MyelomaNCT05317416

Phase 2Q3 2027RitlecitinibKeloidNCT06373458

Phase 2Sep 1, 2027Palbociclib 125Mg TabER+ Breast Cancer, HER2-negative Breast CancerNCT04985266

Phase 3Q3 2027ibuzatrelvirCOVID-19 InfectionNCT07013474

Phase 2Q3 2027PanitumumabCancer, Tumors, NeoplasmNCT02925234

Phase 3Q3 2027MET097Obesity and OverweightNCT07311850

Phase 3Q4 2027ibuzatrelvirCOVID-19 SARS-Co V-2 InfectionNCT06679140

Phase 3Q4 2027PF-08653944Obesity, Overweight and/or Obesity, OverweightNCT07400653

Phase 2Q4 2027PF-08634404Carcinoma, Hepatocellular, Hepatocellular Cancer, Hepatocellular CarcinomaNCT07227012

Phase 2Q4 2027Disitamab vedotinBreast Cancer, Breast NeoplasmsNCT06966453

Phase 2Q4 2027PF-08634404Carcinoma, Renal Cell, Advanced Renal Cell Carcinoma, Renal CancerNCT07227415

Phase 2Q4 2027Heart FailureNCT06991257

Phase 3Q4 2027DazukibartDermatomyositis, PolymyositisNCT06698796

Phase 2Nov 30, 2027Enfortumab VedotinMuscle-invasive Bladder CancerNCT07475806

Phase 2Q4 2027TucatinibBreast CancerNCT05748834

Phase 3Q4 2027PG4Pneumococcal DiseaseNCT07660198

Phase 2Q4 2027PF-08634404Urothelial Cancer, Advanced/Metastatic Urothelial Cancer, Urothelial CarcinomaNCT07421700

Phase 2Dec 31, 2027LHRH AgonistProstate CancerNCT00329043

Phase 3Q4 2027SomatrogonISS, SGANCT07226089

Phase 3Dec 31, 2027Axitinib plus ToripalimabRenal Cell Carcinoma, NeoadjuvantNCT05738694

Phase 2Dec 31, 2027LeuprolideProstate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8NCT06330805

Phase 2Dec 31, 2027Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant SugemalimabLung Cancer (NSCLC)NCT06987734

Phase 2Dec 31, 2027PalbociclibLymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid TumorsNCT02693535

Phase 3Q1 2028ponsegromabCachexia, Metastatic Pancreatic Ductal AdenocarcinomaNCT06989437

Phase 3Q1 2028VLA15Lyme BorreliosisNCT07226882

Phase 3Q1 2028RSVpreF VaccineRespiratory Syncytial Virus (RSV)NCT07768345

Phase 2Q1 2028PF-08049820Atopic Dermatitis, Eczema, AtopicNCT07216027

Phase 3Q1 2028RSVpreFRSV InfectionNCT06866405

Phase 3Feb 28, 2028PalbociclibHPV-unrelated Head and Neck Squamous Cell CarcinomaNCT04966481

Phase 2Q1 2028Relugolix 120 MG [Orgovyx]Prostate CancerNCT06111781

Phase 3Q1 2028PF-08046054Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung CarcinomaNCT07144280

Phase 3Q1 2028Ritlecitinib 100 mgAlopecia AreataNCT06873945

Phase 2Q1 2028PF-08634404Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung CancerNCT07476287

Phase 2Q1 2028Venetoclax; RituximabWaldenstrom Macroglobulinemia, Treatment NaiveNCT05099471

Phase 3Q2 2028PF-08653944Obesity, Overweight and/or Obesity, OverweightNCT07595549

Phase 2May 9, 2028TucatinibMetastatic Breast CancerNCT05892068

Phase 2Q2 2028DexamethasoneAcute Lymphoblastic Leukemia, Lymphoblastic LymphomaNCT06533748

Phase 2Jul 10, 2028AML, Leukaemia (Acute Myeloid)NCT05199051

Phase 2Q3 2028PF-07868489Pulmonary HypertensionNCT07073820

Phase 2Q3 2028BosutinibPhiladelphia Chromosome Positive CML, Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous LeukemiaNCT04258943

Phase 2Q3 2028PF-06835375Primary Immune ThrombocytopeniaNCT05070845

Phase 2Q3 2028PF-08634404Carcinoma, Non-Small-Cell Lung, Lung Cancer (NSCLC)NCT07489066

Phase 3Q3 2028Sigvotatug VedotinNon-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)NCT06758401

Phase 3Q3 2028marstacimabHemophilia A, Hemophilia BNCT05611801

Phase 3Q3 2028MevrometostatMetastatic Castration Sensitive Prostate Cancer (m CSPC), Hormone Sensitive Prostate Cancer, Prostate CancerNCT07028853

Phase 3Q4 2028RimegepantPreventive Treatment of MigraineNCT07729462

Phase 3Q4 2028Multivalent Group B streptococcus vaccineHealthyNCT07160244

Phase 2Nov 18, 2028prifetrastat monotherapy for 15 days then combination with fulvestrantMetastatic (Stage IV) MelanomaNCT07340619

Phase 2Nov 30, 2028DarolutamideProstate Cancer, Advanced Prostate Cancer, Hormone Sensitive Prostate CancerNCT06463457

Phase 2Dec 7, 2028Tucatinib (ONT-380)Metastatic Breast Cancer ( HER2 Negative), Unresectable Breast CancerNCT07193394

Phase 3Q4 2028C.difficile vaccineClostridioides Difficile Associated DiseaseNCT07282665

Phase 2Dec 31, 2028ElranatamabPhase 2, Radiotherapy-Induced Immune Priming, ElranatamabNCT07382739

Phase 3Q1 2029PF-07220060Breast CancerNCT06760637

Phase 3Q1 2029Rimegepant/BHV3000Pediatric MigraineNCT04649242

Phase 2Q1 2029Blinatumomab InjectionB-cell Acute Lymphoblastic Leukemia, B-Cell Acute Lymphoblastic Leukemia, Adult, B-ALLNCT07313852

Phase 3Q1 2029PF-08634404Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell LungNCT07222566

Phase 2Q1 2029PF-08634404Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung CancerNCT07227298

Phase 2Q1 2029Talazoparib with enzalutamideProstate Cancer (Adenocarcinoma), m CRPC (Metastatic Castration-resistant Prostate Cancer)NCT06844383

Phase 2Apr 30, 2029AlectinibCancer, Tumors, NeoplasmsNCT04341181

Phase 2Q2 2029ElranatamabMyelomaNCT06947083

Phase 2Q2 2029PF-06838435 (formerly SPK-9001)Hemophilia BNCT03307980

Phase 3Q2 2029LY4064809Breast Neoplasms, Neoplasm MetastasisNCT07174336

Phase 3Q2 2029PG4Pneumococcal DiseaseNCT07629440

Phase 3Q2 2029tilrekimigAsthmaNCT07772921

Phase 2Q2 2029EtrasimodUlcerative ColitisNCT05287126

Phase 3Q2 2029EtrasimodUlcerative ColitisNCT03950232

Phase 3Jul 1, 2029Abiraterone AcetateRecurrent Prostate Carcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8NCT06650579

Phase 2Q3 2029PF-07248144Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung CancerNCT04606446

Phase 2Q3 2029disitamab vedotinBreast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast NeoplasmsNCT06157892

Phase 2Jul 31, 2029enzalutamideProstate CancerNCT02960022

Phase 2Aug 27, 2029Elranatamab-bcmmMultiple MyelomaNCT07454382

Phase 2Dec 31, 2029ElranatamabMultiple Myeloma, Post-transplant MRD-guided Maintenance Therapy, Pre-transplant PurgingNCT06207799

Phase 2Feb 6, 2030etrasimodPouchitisNCT07486921

Phase 3Q1 2030PF-08634404Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System NeoplasmsNCT07222800

Phase 3Q2 2030PF-08634404Small Cell Lung Cancer (SCLC)NCT07226999

Phase 3Q2 2030Ritlecitinib higher doseSevere Alopecia AreataNCT07029828

Phase 2Jul 15, 2030Brentuximab VedotinHodgkin Lymphoma, Advanced Hodgkin LymphomaNCT07002216

Phase 3Q3 2030PF-06741086Hemophilia A, Hemophilia BNCT05145127

Phase 3Q3 2030Rimegepant (PF-07899801)Acute Treatment of MigraineNCT04743141

Phase 2Q3 2030EtrasimodColitis, UlcerativeNCT07470879

Phase 2Sep 30, 2030LenalidomideMultiple MyelomaNCT06997081

Phase 2Sep 30, 2030CapecitabineMetastatic Breast CancerNCT03424005

Phase 3Q4 2030ElranatamabMultiple MyelomaNCT05623020

Phase 3Q4 2030PF-07275315 dose 1Moderate to Severe Chronic Obstructive Pulmonary DiseaseNCT07363694

Phase 2Dec 1, 2030Elranatamab (PF-06863135)Multiple Myeloma, Newly Diagnosed Multiple Myeloma, Transplant IneligibleNCT07247097

Phase 3Q4 2030OsivelotorSickle Cell DiseaseNCT05431088

Phase 2Q1 2031PF-08154225Systemic Lupus Erythematosus, Rheumatoid Arthritis, Idiopathic Inflammatory MyositisNCT07782450

Phase 2Q2 2031C. difficile vaccine (previously studied formulation).Clostridoides Difficile Associated DiseaseNCT05805826

Phase 3Q3 2031PF-08634404Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer, Gastroesophageal Junction CancerNCT07392892

Phase 3Q4 2031RimegepantMigraineNCT05156398

Phase 2Dec 31, 2031ElrantamabMultiple MyelomaNCT06483100

Phase 3Q4 2031Gemtuzumab ozogamicinAcute Myeloid LeukaemiaNCT02724163

Phase 2Dec 31, 2031ZEN003694Ovarian Cancer, Peritoneal Cancer, Fallopian Tube CancerNCT05071937

Phase 3Q1 2032AbrocitinibAtopic DermatitisNCT06807281

Phase 2Q4 2032ElranatamabMultiple Myeloma, Newly Diagnosed, Multiple Myeloma (MM)NCT06974786

Phase 3Q2 2033Omitted DoxorubicinLeukemia, Acute LymphoblasticNCT04307576

Phase 2Q4 2033Inotuzumab ozogamicinACUTE LYMPHOBLASTIC LEUKEMIANCT05748171

Phase 3Q2 2036ElranatamabMultiple Myeloma, Newly DiagnosedNCT06918002

Phase 3Q1 2040Hemophilia A, Hemophilia BNCT05568719

Phase 2NegativeTBDPD-217,014PainNCT00159640

Phase 3TBDEffexor XRDepressionNCT00225524

Phase 3TBDXalacomGlaucoma, Open-Angle, Ocular HypertensionNCT00150267

PFIZER INC

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Conferences

Recent News & Research

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research